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ABSTRACT
Three Shetland ponies (A, B and C) were inoculated with plasma from 
a pony with clinical signs of equine infectious anemia (EIA) and observed 
for 165 to 440 days. Clinical signs of EIA marked by high fever 
( 39.5°C) lasting 2-4 days were observed 2-3 weeks after infection and 
one to four such episodes occurred in each pony. EIAV was reisolated 
from plasma by end-point dilution in fetal equine kidney (FEK) cells and 
a plasma viremia 103-5 TCID50/ml was observed during each episode. A 
total of seven virus isolates were recovered.
Cross-neutralization tests with sequential serum samples showed that 
the four viruses isolated from pony A during febrile episodes 4-5 weeks 
apart were serologically different. Tryptic peptide map analysis of these 
isolates revealed additions or deletions between each isolate and its
immediate predecessor. .Western blot analysis of these four isolates 
including those from ponies B and C with a panel of monoclonal 
antibodies confirmed antigenic variation in both gp90 and gp45. Both 
conserved and variable epitopes were identified in each glycoprotein with 
greatest variation in gp90. Analysis with MAbs confirmed similar
antigenic variation in an in vitro variant generated in cell culture.
The humoral response to EIAV was monitored for anti-virus
antibodies by AGID, Western blots and a novel single-step immunoblot 
devised in this study for rapid assay of EIAV antibodies and antigens.
Specific IgG directed against determinants of EIAV gp90, gp45 and p26 in 
homologous and heterologous virus isolates was detectable within one 
month after infection. The group-specific determinants in gp90 and gp45 
were more antigenic than those in p26. Neutralizing antibodies first
detectable within two months were observed to be effective only to 
viruses isolated prior to serum collection but became broadly reactive 
later in the infection regardless of the number of clinical episodes.
Our data showed that rapid antigenic variation occurred during 
persistent infection with EIAV in ponies and in cell culture in the 
presence of immune serum, and neutralizing antibody response broadened 
during the course of EIA. The conserved antigenic determinants of EIAV 
gp90 and gp45 identified in this and previous studies will be useful in 
diagnostic procedures and may have potential for vaccines against EIA.
CHAPTER ONE
LITERATURE REVIEW
EQUINE INFECTIOUS ANEMIA (EIA): A LENTIVIRUS DISEASE OF
HORSES.
Equine infectious anemia (EIA) is a naturally occurring viral disease 
of all Equidae. The disease has a world-wide distribution and is
characterized by recurrent episodes of fever, hemolytic anemia, bone
marrow depression, lymphoproliferation, a life long persistent infection 
and immunologically-mediated lesions (18, 29, 36, 68, 107). The etiological 
agent of EIA is an exogenous replication competent retrovirus that is 
more closely related to the lentiviruses than to the other subfamilies of 
retroviruses (15, 16, 56, 125, 133, 165). The disease has a variable 
clinical course; but in natural infections, the disease is mostly inapparent 
(77). The nature of EIA virus (EIAV) induced clinical signs, the presence 
of immunologically mediated lesions and the relatedness of this equine 
virus to both human and other animal lentiviruses make EIA a good model 
for the elucidation of mechanisms involved in the persistence of viral 
infections in immunologically responding hosts. In addition, it may be 
useful for the evaluation of various chem otherapeutic and 
immunoprophylactic protocols for the control of rapidly evolving viruses. 
Thus, an evaluation of the mechanisms involved in the persistence of 
EIAV in susceptible horses is paramount in the eventual design of 
effective disease control protocols. Foremost amongst these is
understanding how horses respond immunologically to EIAV, and how
1
antigenic drift may be responsible for the recurrence of febrile episodes 
in chronic EIA. The detailed serological and biochemical analyses of 
viruses isolated from horses with either acute or chronic EIA may aid in 
estimating the degree of antigenic and genetic variation in EIAV.
Equine infectious anemia has a variable clinical course. Horses that 
are infected with equine infectious anemia virus (EIAV) display a 
spectrum of disease conditions that range from an inapparent state to a 
chronic infection that is accompanied by recurrent disease episodes. 
Following primary exposure to EIAV, horses may remain inapparent for 
long periods or have an acute disease that may result in death or 
recovery. Horses that survive an acute episode may in turn become 
inapparent carriers or progress to a chronic infection. In natural cases
of EIA a great majority of the horses are inapparent carriers of the virus 
and are only discovered when their serum tests positive for anti-virus 
antibody (77).
Acute EIA is most often associated with the first exposure to the 
virus. The incubation period varies from 5 days to as long as several 
months depending upon the virus isolate used, the amount of virus given, 
the host resistance and environmental factors (82). Pyrexia (>39.5° C), 
which lasts for 3 or 4 days, is the most characteristic clinical sign and is
generally evident from 7 to 30 days after infection. Horses with acute
EIA are often not diagnosed since precipitating antibodies detectable in 
the agar gel immunodiffusion (AGID) test peak at about 3 to 4 weeks 
after infection (29). During the peak of the febrile response, high 
viremia is often found and viral antigen can be demonstrated in many 
body organs, particularly in those rich in macrophages (91, 106). The
virus is thought to cause a lytic infection of macrophages (87, 106). 
Most horses with acute EIA survive and may go unnoticed as the classical 
signs of the disease, i.e. weight loss, anemia and ventral edema, are 
usually not evident during this first episode (77).
Following the initial infection, chronic EIA may develop. It is 
characterized by the occurrence of unpredictable recurrent clinical 
episodes that may be several weeks to months apart (91). The number 
and the frequency of such episodes is variable but tends to decline with 
time and about 90% occur within one year of infection (91, 122). Horses 
with chronic EIA are positive in AGID test and depict most of the signs 
associated with EIA including fever, loss of weight, weakness, anemia, 
ventral edema and terminal depression (122).
The level of cell-free viremia in horses with chronic EIA is variable 
but is highest during the recurrent febrile episodes when it reaches 
104/m l of plasma for 2 to 3 days before subsiding (91). Horses with 
chronic EIA are apparently normal between febrile episodes; isolation of 
virus from plasma during afebrile periods is difficult and may be 
indicative of low levels of circulating cell-free virus. The repeated 
massive outpouring of virus and associated antigens in the face of a 
vigorous immune response sets in motion a series of immunopathological 
events that cause the clinical signs and lesions of EIA and include 
anemia, infectious immune complexes and glomerulonephritis (67, 107, 139). 
Mares that become infected while carrying a foal may either abort or 
deliver infected foals depending on the clinical course (81). After an 
unpredictable number of recurrent febrile episodes, most horses stop 
cycling and remain inapparent carriers of EIAV. However, a number of
EIAV infected horses may fail to show any signs of disease but remain 
inapparently infected (77). Horses that have been apparently normal for 
a long period of time may suddenly re-experience an acute febrile 
episode. Moreover, such inapparently infected horses may be induced to 
experience clinical EIA by exposing them to environmental stress such as 
hard work or by immunosuppressive therapy, such as multiple doses of 
dexamethasone (77, 92). These data all indicate that once horses are 
infected they remain virus carriers for life, irrespective of the course of 
the disease.
EIAV can be naturally transmitted from acutely ill horses by the 
interrupted feeding of horse flies (79). Since the virus has not been 
shown to multiply within insects, the only known mode of transmission 
other than in utero is mechanical (145). Mechanical transmission of EIAV 
can also be affected by the transfer of blood or blood products on 
contaminated instruments or syringes. The success of mechanical 
transmission of viruses depends on many variables including the level of 
viremia at the time of feeding (or transfer of body fluids), the survivab­
ility of the virus outside the natural host, the population density of both 
the natural host and the transmitting insect(s) and the seasonality and 
the feeding habits of the insect vector population. Within the U.S., 
Louisiana has the highest reported incidence of EIA (78).
Diagnosis of EIA currently depends on the detection of precipitating 
antibodies in the AGID test, popularly known as the Coggins test (28). 
The test is based on the detection of antibodies reactive to the viral 
antigens, particularly the major core protein, p26, which contains group 
specific determinants. The correlation between AGID-seropositivity and
the presence of infectious virus in the blood of test horses may approach 
100% (30). Although other more sensitive serological tests including 
immunofluorescence (35), radioimmunoassay (32), and enzyme linked 
immunosorbent assay (140) have been developed, they are rarely used. 
Like all other serological tests based on the detection of serum antibody, 
the diagnosis of EIA by AGID is limited to the phase of the disease when
precipitating serum antibody is present. Other diagnostic procedures that
have been used in the diagnosis of EIA include hematology, pathology, 
and the horse inoculation test (77).
RETROVIRUSES AND THEIR CLASSIFICATION.
Retroviruses are classified according to their morphology, the struct­
ure of their RNA viral genomes (a dimer of two identical subunits of 
single-stranded RNA (30S-40S) of positive or messenger sense polarity),
and their RNA-dependent DNA polymerase (reverse transcriptase) (47). 
Retroviruses are widely distributed among vertebrate species, including 
mammals, birds, and reptiles (154). The process of reverse transcription
in the expression of genetic information is a strategy utilized not only by 
the retroviruses, but also by hepadnaviruses, as well as viruses infecting
insects and plants (73). The family Retroviridae is divided into three 
subfamilies: 1) Oncovirinae, including all the oncogenic members and
many closely related nononcogenic viruses; 2) Lentivirinae, the "slow" 
viruses, such as visna virus; and 3) Spumavirinae, the "foamy" viruses
that induce persistent infections without any classical disease (154).
Lentiviruses are so named because they cause diseases with long
incubation periods, insidious onsets and slowly progressive courses (61).
The prototype members of this subfamily of retroviruses include a number 
of viruses that have been isolated from sick sheep and goats in various 
locales. These viruses include visna, maedi (59), zwoegerziekte (40), 
progressive pneumonia virus (PPV) (83), and caprine arthritis encephalitis 
virus (CAEV) (34). Other lentiviruses include: equine infectious anemia 
virus (EIAV) of horses (15); a number of related retroviruses that have 
been isolated from immunodeficient (39) and asymptomatic monkeys (80); 
and the retroviruses associated with the acquired immunodeficiency 
syndrome (ADDS) in humans, the human immunodeficiency virus (HIV) (10, 
23,27,57)
MORPHOLOGY.
Mature EIA virions are enveloped spherical particles that are 110 to 
120nm in diameter (158). The external surface of the virion envelope 
contains glycoprotein projections (spikes and knobs) that are 10 to 12nm 
in length (158). The core of the virion is remarkably pleomorphic and 
ranges from cone shaped to tubular (158). An inner particle shell is 
located between the core and the envelope. Ultrastructurally EIAV 
closely resembles visna virus and the other members of the subfamily 
lentivirinae (56). Recent evidence indicates that members of the 
subfamily lentivirinae are morphologically related and "mature" particles 
contain a condensed central core, which depending on the section plane, 
appear eccentric, bar-shaped, triangular or oblong (13, 50, 57). Mature 
EIA virions acquire their envelope by budding from cytoplasmic 
membranes, both into cytoplasmic vacuoles and extracellularly (56).
PHYSICOCHEMICAL PROPERTIES OF EIAV.
The physicochemical properties of EIAV are those of enveloped 
viruses in general but those of retroviruses in particular. Mature EIA 
virions are enveloped and have a buoyant density of about 1.16 g/ml in 
cesium chloride (16, 102). Virion infectivity is sensitive to ether and 
detergents but is resistant to trypsin treatment at 37°C, ultra-violet and 
X-irradiation (114). Virus infectivity is inactivated following treatment 
with a variety of chemical disinfectants including sodium hydroxide, so­
dium hypochlorite, organic phenolic compounds and chlorhexidine (144). 
In horse serum, EIAV has been reported to be inactivated by treatment 
with 56°C for 60 min (9). EIAV has been mechanically transmitted to 
horses by groups of 25 horse flies 30 min but not 4 hours after they had 
taken a partial blood meal from an acutely infected donor (66).
The cell adapted Wyoming strain of EIAV (98) has been the source of 
virus for most the majority of published reports on EIAV since 1974. 
Purified EIAV has been characterized extensively. It is composed of the 
following: a high molecular weight RNA (60 to 70S) made of two identical 
linear subunits that are noncovalently bound near their 5’end; a RNA- 
dependent DNA polymerase (reverse transcriptase) that has a preferential 
requirement for Mg++; a lysine-specific tRNA molecule noncovalently 
bound near the 5’ end of each genomic RNA and functions to prime 
reverse transcription and 6 major structural polypeptides analogous to 
those of prototype C-oncogenic retroviruses (6,15,16,112,125).
VIRAL GENOME: STRUCTURE AND EXPRESSION.
The genome of EIAV possesses the three classical genes found in all 
replication competent retroviruses (26). These are the gag gene which 
codes for the internal structural proteins, the pol gene which codes for 
the reverse transcriptase, and the env gene which codes for the envelope 
proteins. The transcription of retroviral message proceeds through a 
DNA intermediate, the provirus. The provirus represents a 
transcriptional unit that contains its own gene expression regulatory 
sequences within the long terminal repeats (26,155).
Retroviruses are composed of about 60-70% protein, 30-40% lipid, 2-4% 
carbohydrate and 1% RNA (154). Purified EIAV contains structural 
polypeptides analogous to those of avian and murine type C-oncoviruses 
and include two envelope glycoproteins and four major internal non­
glycosylated proteins (112, 125). The relative molecular weights of EIAV 
structural proteins in sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) are 90,000 daltons and 45,000 daltons, 
respectively, for the two surface glycoproteins (gp), gp90 and gp45 and 
core proteins of 26,000, 15,000, 11,000 and 9,000 daltons, respectively 
(p26, pl5, p l l ,  p9) (8, 125). In addition to the six main structural 
proteins four minor polypeptides (p70, p61, p30 and p23) are revealed in 
SDS-PAGE (125). These minor polypeptides could be components of the 
virion reverse transcriptase or uncleaved precursors for the structural 
proteins.
The gag gene products are translated from a complete viral messenger 
RNA and processed from a polyprotein (NH2-pl5-p26-pll-p9-COOH) to 
form the inner core of the virus (112, 125, 148). The core of the virus
encloses the ribonucleoprotein complex which is composed of viral RNA, 
the basic protein p l l  and 6-10 copies of the reverse transcriptase. The 
most abundant structural protein is p26 which forms the core shell with 
the acidic protein p9. The fourth core protein is pl5 which forms a 
continuous inner coat or mantle beneath the lipid bilayer (112,125).
The virus glycoproteins are translated from a spliced messenger RNA 
that corresponds to the 3’-terminal end of the viral genome and are 
subsequently processed from a polyprotein precursor (42). The env gene, 
2577 bases long, encodes the virion envelope glycoproteins in the order 
NH2-gp90-gp45-COOH (135). Partial digestion of purified virus with 
bromelain completely removed the two viral glycoproteins indicating their 
location on the surface of the virion (112). The major envelope 
glycoprotein (gp90) is heavily glycosylated (125, 135). In contrast, gp45 
is a less glycosylated and highly hydrophobic glycoprotein that is 
associated with the lipid bilayer (125, 135). The spikes and knobs 
observed in mature EIA virions represent gp45 and gp90, respectively 
(112, 135, 158). Analogous to other enveloped virus systems, the major 
envelope glycoprotein of EIAV, gp90 probably mediates important 
functions in the virus replication cycle including host receptor recognition 
and may be the primary target for antibody-mediated virus neutralization 
(111, 112). Monoclonal antibodies specific for gp90 neutralize virus 
infectivity in cell culture (74). It is thus probable that antibodies to 
gp90 mediate virus neutralization in vivo.
Apart from the characteristic retroviral genes, gag, pol and env, the 
lentiviruses possess other open reading frames whose translation products 
may be related to their unique biology. The EIAV genome contains three
10
such open reading frames SI, S2 and S3 (135) that may have functions 
analogous to those documented for HIV (19).
Hybridization studies using cDNA (17, 133) or molecularly cloned 
EIAV probes (165) have clearly demonstrated that EIAV is an exogenous 
mammalian retrovirus. Moreover, genetic comparisons of EIAV with other 
lentiviruses have demonstrated that EIAV is more closely related to this 
subfamily of retroviruses than to the oncoviruses (20, 137, 165).
Furthermore, group specific and interspecies determinants of EJAV cross 
react with human and ovine lentiviruses in immunological assays (109, 137, 
165). Sera from horses infected with EIAV recognize the major core 
protein, p24 (109) and the major envelope glycoprotein, gpl20 (137) of 
HIV-1. The genetic comparisons of EIAV with prototype lentiviruses 
have provided more definitive evidence for the assignment „of EIAV as a 
lentivirus and confirm earlier assignments that were based on serological 
and morphological similarities (6,15,56,57,109).
INTERACTION OF LENTIVIRUSES WITH THEIR HOSTS.
The initial event in the life-cycle of viruses is the attachment to 
specific receptors on the cell surface (150). In many cases, this event is 
a major determinant .of virus tropism in pathogenesis (141). Different 
viruses utilize different specialized cell structures as receptors (37): these 
viral receptors have important host functions (25) and in most cases 
internalize specific ligands by receptor-mediated endocytosis (54). 
Lentiviruses infect a variety of cells wherein they cause lytic or persis­
tent infections depending on the virus and the cell type. The prototype 
lentivirus visna virus undergoes an acute lytic cycle in cultured sheep
11
choroid plexus (SCP) cells in which the yield of viral progeny is high. In 
the same cell type, CAEV causes a non-lytic infection in which the yield 
of progeny virus is 1000-fold lower than that of visna virus (116). The 
cell culture-adapted Wyoming (98) strain of EIAV (prototype EIAV) causes
persistent infections in equine fibroblasts including those derived from
primary fetal equine kidney cell cultures (16). The prototype EIAV has 
been observed to cause cytopathology in fetal donkey dermal cells
(McManus, unpublished results).
In contrast to the animal lentiviruses, HIV does not infect cultured 
fibroblasts and epithelial cells (95). The restriction of HIV to infect 
these cells is predominantly due to the absence of surface receptors. 
Transfection of cultured fibroblasts with a molecular clone of HIV (ARV- 
2) showed that the virus can replicate in cells from several mammalian 
species; however, the virus replicated better in human than in mouse 
derived fibroblasts (96). Transfection of tumor cells with the isolated 
CD4 complementary DNA demonstrated that CD4 expression was the sole 
requirement for virus to infect target cells (105). Although the 
lentiviruses infect a variety of cultured fibroblasts, studies with the 
ruminant lentiviruses indicate that the target cells in the persistently 
infected animal are the monocyte-macrophages and not the fibroblasts 
(116, 117). However, fibroblasts and possibly other cell types, may be 
more involved in the pathogenesis of persistent lentiviral infections than 
previously thought. Indeed, the prototype EIAV can be reisolated in
primary fetal equine kidney cell cultures even after multiple passages in 
Shetland ponies (122).
The mononuclear phagocytic system (monocytes and macrophages) is
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considered to be one of the primary non-specific defense mechanisms 
against foreign agents including viruses. In addition, these cells are 
involved in the induction, regulation and amplification of the immune 
system, thus playing a central role in eliminating viruses from the 
infected host. The ability of viruses to infect these cells may be crucial 
to their persistence since latently infected cells can exist in the 
presence of neutralizing antibodies. Such latently infected cells may, in a 
manner analogous to the Trojan horse, serve as reservoir and/or vehicle 
for virus dissemination in an immunologically responsive host (128). Thus, 
viruses that are capable of invading these cells can very readily evade
the immune system. Furthermore, these cells can take in viruses by 
specific (virus receptors) as well as by non-specific (Fc-receptors) 
mechanisms, thus making them a favorable target cell population for many 
viruses.
A number of viruses have a predilection for the mononuclear
phagocytic system wherein virus replication, persistence, and spread in 
the host occurs as a result of the infection of these cells. The
monocyte-macrophage series has been implicated in the pathogenesis of 
lentivirus infections because viral antigens, viral genomes and/or virus
replication can be demonstrated in this cell population by a variety of 
techniques including immunofluorescence, immunocytochemistry, m situ 
hybridization, and electron microscopy (86, 106, 128). Moreover, infe­
ctious virus can be isolated from these cells by cocultivation with 
susceptible cell lines and macrophages readily support virus replication in 
vitro (5,51, 95,116)
The unique biology of lentiviruses can best be exemplified by HIV
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which infects a number of cell types and causes an immunodeficiency in 
humans that becomes clinically apparent years after the initial infection. 
The virus infects a number of cell types that bear the CD4 molecule on 
the surface. HIV infects T4 lymphocytes where it causes lytic or persist­
ent infections (10, 14, 38, 48, 72, 85, 105, 129). The virus also replicates 
in non-T lymphoid cell types including normal blood-derived monocytes, 
macrophages, EBV-transformed B-lymphocytes, malignant glioma cells and 
human monocytoid cell lines (7, 21, 93, 95, 110, 119). The virus has been 
isolated from human peripheral blood leukocytes (PBL) and alveolar 
macrophages of AIDS patients and causes a persistent infection in 
cultured PBLs (21, 49, 93, 95, 119). This non-cytopathic infection of 
monocytes and macrophages is probably due to a lower surface density of 
CD4 molecules: the CD4 glycoprotein appears to be an integral component 
in HIV-induced cell killing. However, as these cells harbor HIV proviral 
DNA they may serve as a  reservoir for virus persistence in the host (58, 
86, 93, 143). Isolates of HIV may differ in their ability to productively 
infect human cells (46). As in the animal lentiviruses, the factors 
involved in the restriction of virus replication in vivo are not known but 
may include cytokines e.g., interleukins, interferons and intercurrent 
pathogens e.g., EBV, cytomegalovirus and hepatitis B infections.
In contrast to the high yield of viral progeny in vitro, the replication 
of lentiviruses is severely restricted in vivo and with the exception of
ELA where high levels of plasma viremia occur during clinical disease
episodes, cell-free virus is not detectable in the other lentivirus
infections. In ELA, macrophages are the only cells identified which
harbor the virus and support replication of the wild-type virus (88, 106,
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149). In some asymptomatic horses infectious virus cannot be demonstra­
ted in the serum or whole blood but the infection can be transmitted 
with washed leukocytes (31). Thus, in a manner analogous to the other 
lentiviruses, EIAV probably infects many cell types including promyeloc­
ytes, monocytes and macrophages (51, 95, 116). Lentivirus replication 
may be intricately associated with the functional status of these cells. In 
visna, only a small proportion of monocytes is infected and virus 
replication is associated with the maturation of monocytes to macrophages 
(51, 52). Virus replication appears to be restricted at the transcription 
level (52, 128) apparently through a complex interaction involving infected 
monocyte/macrophages, T-lymphocytes and a lentivirus-induced interferon 
(118). In infected sheep, virus replication is repressed in many cell types 
including the monocyte/macrophages in tissue fluids with neutralizing 
antibody (128). In a similar manner, HIV genome expression appears to 
be repressed and high levels of genome expression are only observed after 
prolonged mitogenic stimulation of mononuclear cells from AIDS patients. 
The repressed state of lentivirus replication in vivo suggests that these 
viruses can persist in the face of a vigorous immune response as most 
infected cells are not producing viral antigens and escape detection by 
the immune surveillance mechanism.
As with other retroviruses, lentiviruses can persist in susceptible cells 
by integrating their DNA proviruses into host cell DNA (155). Once 
integrated, the provirus is replicated and duplicated equally to daughter 
cells along with the host DNA, thus ensuring survival of the viral 
genome. In lentivirus infections, both integrated and unintegrated 
proviruses have been demonstrated in cultured cells and in cells or tissues
from infected individuals (17, 65, 133, 142, 164). The replication cycle of 
visna virus in cultured cells occurs without provirus integration (65). The 
biological significance of the level of provirus integration observed in 
lentivirus infections is not known but may be related to the exogenous
nature of this subfamily of retroviruses (62).
ANTIGENIC VARIATION
The survival of parasites in their target hosts is continuously 
challenged by the immunological mechanisms involved in host protection. 
Faced with these immunological barriers, parasites have improvised growth 
strategies whose sum enable them to persist in their hosts. The 
repertoire of these growth strategies includes: partial or complete genetic 
changes involving parasite surface structures; growth in cells of the
immune system including lymphocytes, monocytes and macrophages; growth 
in parts of the body with less vigorous immunological surveillance (e.g. 
CNS); and an inability to express parasite antigens for long periods, i.e. 
latency. The games that parasites play are best exemplified by a 
consideration of the survival mechanisms displayed by the African
trypanosomes and the influenza virus.
The antigenic properties of the African trypanosomes are due to a 
single glycoprotein, the variant surface glycoprotein (VSG). Each 
trypanosome contains over 100 VSG genes whose products are 
serologically and biochemically different (11). Antigenic variation,
mediated by sequential expression (via DNA recombination) of the VSG 
genes, is the primary mechanism for the survival of trypanosome popula­
tion in immunologically responding hosts.
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Viruses with RNA genomes evolve by a variety of means. These 
include reassortment of gene segments, recombination between homologous 
nucleic acid molecules, point mutations, sequence repetition, deletion and 
inversion. Reassortment of virus genomes occurs with viruses that have
segmented genomes regardless of their strandedness or complement of 
strand segments (124). If cells are infected with two related viruses, 
there can be an exchange of homologous gene segments with the 
production of different stable reassortants.
Two distinct kinds of antigenic variation have been demonstrated in 
influenza A viruses; antigenic shift and antigenic drift. Antigenic shift in 
type A influenza virus occurs infrequently when a "new" virus suddenly 
appears with hemagglutinin (HA) and/or neuraminidase (NA) molecules of 
a subtype different to those of the virus circulating before the new virus 
appealed. Antigenic shift is thought to occur when: 1) genetic
reassortment occurs between human and animal or human viruses; and 2) 
animal or bird influenza A viruses undergo mutations which allow them to 
become infectious for humans (3).
At more frequent intervals, minor changes termed antigenic drift, 
take place in one or both of the surface glycoproteins (HA and NA). 
Antigenic drift in influenza A virus occurs by point mutations in the HA 
and NA genes that lead to a gradual accumulation of amino acid sequence 
changes that alter the epitopes in such a way that they no longer are 
recognized by existing specific immune effector mechanisms. Although 
each episode of drift may be minor, the effects are additive and over a 
period of several years result in a virus showing a considerable degree of 
antigenic difference from the original pandemic virus. The point
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mutations are predominantly in the amino terminal end of the HA gene 
and cluster to four antigenic sites in the native HA polypeptide. 
Antigenic analysis of HA with monoclonal antibodies (MAbs) and 
polyspecific antisera revealed that epidemiologically significant strains 
sustain point mutations at two or more antigenic sites; a large number of 
mutations are required for complete resistance to polyspecific antisera (3, 
12,146,157,167).
In visna, new virus strains do not successively replace parental virus;
both the inoculum strain and the variant strains can be isolated from
peripheral blood leukocytes simultaneously. The new strains of visna
virus have been shown to arise by point mutations in the env gene which
result in structural alterations in the major envelope glycoprotein, gpl35 
(24, 138). In most cases, visna virus persists and spreads without the 
emergence of new virus variants (97, 153). Besides the repressed state of 
visna virus genome expression in monocyte/macrophages, visna virus can 
infect these cells in the presence of "neutralizing" antibodies indicating 
that antigenic variation is not critical for the survival of this virus in 
immunocompetent hosts (84).
In chronic EIA there are cycles of virus replication in which virus 
can be isolated from plasma. Neutralization studies using polyclonal sera 
obtained from rabbits immunized with purified virus demonstrated the 
existence of antigenic drift in EIAV (91). Each new virus isolate from a 
cycle is refractory to neutralization by antibody that neutralized previous 
EIAV isolates (91, 123, 136). Recent studies have further documented 
that viruses recovered from sequential febrile episodes are structurally 
and genetically unique (127, 136). Western blot analyses of EIAV isolates
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revealed that antigenic alterations occurred predominantly in the major 
envelope glycoprotein, gp90 (74). The survival of EIAV in 
immunologically responsive hosts appears to be mediated by antigenic 
variation. From this standpoint, it is imperative to determine the extent 
to which this virus varies and exists in susceptible animal populations 
before any immunoprophylactic or chemoprophylactic intervention can be 
contemplated.
The contention that lentiviruses demonstrate rapid genomic changes 
has recently been extended by results from the analysis of HIV isolates 
obtained from the same or different individuals (64, 163). Analysis of 
HIV-1 isolates from different geographical regions revealed extensive 
genomic variation particularly within the region encoding the viral 
envelope glycoprotein (4, 63, 162, 163). A similar variability has been 
observed in viruses sequentially isolated from persistently infected 
individuals (64). Viruses isolated from one individual are more genetically 
related to each other than to viruses isolated from other individuals and 
may therefore have evolved in parallel from a common progenitor (64, 
163); virus interference may exclude superinfection with many strains of 
HIV. The genetic variability of HIV results largely from small duplica­
tions, insertions or deletions as well as from numerous point mutations in 
the envelope gene (63, 63, 162). Within the env gene, hypervariable 
regions are interspersed with regions of strong conservation (131, 147, 
162). Complementing the sequence data, serological studies have shown 
that HIV-1 isolates are antigenically heterogeneous (22, 103, 159). HIV-2 
is genetically and antigenically more closely related to the simian 
immunodeficiency virus (SIV) than to HIV-1 (23, 60). Molecular and
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serological data indicate that HIV is as highly mutable as the animal
lentiviruses (24,127).
Like RNA viruses in general, lentiviruses have high mutation frequen­
cies due to the lack of error correcting mechanisms in genome replication 
(132). The estimated error rate for RNA replicases lies between 103 and 
10-4 (71, 132) and is therefore of the order of 104- to lOMbld greater
than the mutation rates of stable DNA genomes (69, 71). Replication of 
RNA is therefore an intrinsically "noisy" process (132). The noisiness of 
RNA replicases means that the genomes of RNA viruses are not
monolithic, but are constantly evolving irrespective of the attested 
homogeneity of any starting virus population (69). Analyses of lentivirus 
genomes by Tl-oligonucleotide mapping, Southern blot, restriction enzymes 
and nucleotide sequencing reveal that genomic variations range from
slight to rather extensive changes; such changes are observed with
highest frequency in the env gene and are compatible with the expected 
mutational rates of RNA viruses (64, 113, 136, 163). These genomic 
changes may result from errors associated with reverse transcription and 
from genetic recombination during mixed infections with related viruses.
The viral glycoproteins are involved in host-cell recognition and may 
be the primary targets for antibody mediated neutralization. The role of 
envelope glycoproteins in eliciting neutralizing antibodies has been
established for a number of viruses including feline leukemia virus gp-70
(121), influenza virus hemagglutinin (156), herpes simplex virus glycopro-
tein-D (33), rabies virus glycoprotein-G (161), human immunodeficiency 
virus gpl20 (160) and EIAV gp90 (74). Thus from an immunoprophylactic 
point of view, knowledge of the structure, immunogenicity, antigenicity
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and variability of the surface glycoproteins of lentiviruses is imperative.
Specific antibodies exert antiviral effects via several distinct 
mechanisms. First, intrinsic neutralization may occur. This mechanism 
involves loss of virus infectivity mediated by the direct binding of 
antibody to neutralization antigenic sites. In some cases, bound antibody 
may mediate neutralization only in the presence of complement or anti­
globulin. Second, extrinsic neutralization may result in the loss of virus 
infectivity due to an inhibition of virus adsorption which results from 
antibody binding at or nearby the viral attachment proteins. In 
enveloped viruses, antibodies attached to the envelope glycoproteins can 
also mediate neutralization by complement-mediated lysis of the virus 
membrane. A third mechanism, pseudoneutralization, which may function 
under certain conditions, e.g., at equivalent concentrations of virus and 
antibody, results in loss of virus infectivity by promoting formation of 
lattice like aggregates of infectious virions. Low affinity antibodies e.g., 
IgM and early IgG tend to have higher levels of "sensitized" virus. 
Moreover, the cell type and the environmental conditions may also 
contribute to this phenomenon (43,104, 111, 120).
Antibodies can neutralize poliovirus by inducing conformational 
changes in the capsid (44, 45, 99). These changes may result in an 
alteration of molecular functions including loss of efficient virus 
adsorption to host cells. Cross-linkage of pentameric subunits of the 
virus capsid (76) or aggregation of virus particles (2) result in poliovirus 
neutralization. Conformational alterations in the viral capsid may result 
in the physical loss of viral genome causing irreversible loss of infectivity 
as exemplified by foot-and-mouth disease virus (104).
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Although the attachment of virus to host cells can be prevented by 
neutralizing antibody, e.g. reovirus infection of L-cells (94), in most
cases, the binding of neutralizing antibodies to virions does not inhibit 
virus attachment to host cells. This may be because the cellular binding 
site is distinct from the epitopes involved in neutralization, e.g. with
influenza virus (134). Antibodies that neutralize influenza virus do not 
inhibit attachment, penetration, uncoating of virus or transport of the 
uncoated RNA into the nucleus. Moreover, the mechanism of virus
neutralization may depend on the antibody isotype. Thus, monomeric IgG 
probably neutralizes influenza virus by inhibiting the function of the viral 
transcriptase (130), while polymeric IgA and IgM may neutralize the virus 
by steric hinderance of the viral receptor "pocket" in the HA (151, 152). 
Antibody induced conformational changes may result in the neutralization 
of enveloped viruses by inhibition of a low-pH mediated fusion reaction 
between the membrane of the virus particle and that of a prelysosomal 
endosome, thus impairing the entry of viral cores into the cytosol as has 
been shown with the West Nile virus (55). The different modes of action 
of the varibus immunoglobulin classes, the different viruses and the 
different cell systems used by many investigators may help to explain why 
virus neutralization is still a controversial subject.
It is generally accepted that immune selection pressure operates in 
the selection of virus mutants during antigenic drift. Antigenic drift has
been mimicked in the laboratory by the propagation of viruses in the 
presence of low levels of neutralizing polyclonal antisera or monoclonal 
antibodies. Such studies have been conducted for a number of human and 
animal viruses including the human influenza A viruses (53), poliovirus
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type 1 (41), herpes simplex virus (70), foot-and-mouth disease virus (75), 
and visna virus (115). A general outcome of propagating these viruses in 
the presence of neutralizing antibodies has been the emergence of virus 
variants that resisted neutralization by the selecting antibody. Chronic 
EIA, characterized by recurrent febrile episodes, is thought to be induced 
by novel virus variants (90) that probably arise through random virus 
genome mutations and antibody selection pressure. Thus, generation of 
neutralization escape mutants of EIAV in cell culture would aid in 
substantiating the role of antibody in antigenic drift. Antigenic and 
genetic analysis of neutralization escape mutants may identify the changes 
associated with the ability of virus variants to elude host immunological 
controls.
In infections of horses with EIAV, serum neutralizing antibodies have 
not been detected earlier than 45 days after infection and peak titers 
occurred later in the course of the disease (89). This raises the 
question of the nature of both specific and non-specific immunological 
controls operative in the recovery from acute EIA in the absence of 
demonstrable neutralizing antibody. Furthermore, the effectiveness of
neutralizing antibodies is periodically circumvented by the ability of the 
virus to change antigenically (90) thus allowing virus mutants to replicate 
until immunological controls are reestablished. Eventually, horses with 
chronic EIA cease to have recurrent febrile episodes but remain
inapparently infected for life. It is not clear how much antigenic
relatedness exists between viral isolates. If present, it is apparently 
minor and inadequate to stimulate cross-protection by antibody (90, 91).
Most horses mount a vigorous humoral and cell-mediated immune
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(CMI) response to most if not all EIA antigens and CMI may be the 
principal mechanism involved in long term host protection against 
recurrent EIA (108). Indeed, when asymptomatic horses were treated with 
dexamethasone or cyclophosphamide, viremia and clinical disease occurred 
(92). The time interval between treatment and disease expression was too 
short to be explained by an effect on antibody levels. Furthermore, 
horses with chronic EIA resisted infection by serotypes to which they had 
no demonstrable neutralizing antibody, which suggests that immunological 
factors other than antibody participate in protecting horses from 
recurrent febrile episodes (90). In viral infections, a T-cell mediated 
immune response may be the most important regulator of the host to 
infection. Thus, the induction of a CMI response may be an important 
component of the overall immunity directed towards viruses. Although 
definitive mechanisms of CMI responses have not been obtained in EIA, 
evidence from influenza virus indicates that viral envelope glycoproteins, 
as well as internal viral proteins, are involved in the generation of 
serotype-specific and cross-reactive cytotoxic T lymphocytes (CTLs), 
respectively (1). Although the internal viral proteins are involved in the 
generation of cross-reactive CTLs, vaccination of mice with recombinant 
vaccinia virus containing the nucleoprotein (NP) of influenza virus did not 
induce complete protection (167) indicating that HA is required for 
complete protection to occur; this implies that strain specific neutralizing 
antibodies and CTLs are important in the primary defense against 
influenza virus infection.
A major challenge in the control of viruses that evolve as rapidly as 
EIAV is development of effective vaccination protocols. A combination of
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molecular and genetic studies of the lentiviruses has shed light on some 
unique properties of these viruses, especially their ability to evolve 
rapidly. However, fundamental aspects of the mechanisms by which these 
viruses are transmitted from host to host and how they persist within 
immunoresponsive hosts need to be identified. A better understanding of 
the pathogenetic mechanisms of EIAV and the immune responses important 
in host protection is desirable for a rational assessment of strategies for 
vaccine development.
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RESEARCH OBJECTIVES.
Equine infectious anemia is a disease of horses that occurs 
throughout the world. The disease tends to have a recurrent course and 
infected horses carry the virus for life. Recurrent episodes of EIA are 
thought to be due to the emergence of novel variants of EIAV that
escape immunological controls existent at the time of their emergence. 
Recent studies have shown that EIAV mutants readily evolve in infected 
animals. To date, no form of chemotherapeutic or immunological 
intervention in EIA is in use. For any of these measures to be 
anticipated or even attempted, a detailed analysis of the mechanism(s)
involved in the persistence of EIAV needs to be achieved. Thus, an 
assessment of the repertoire of serotypes of EIAV and their relatedness 
to each other is central to any attempt to control this important viral 
disease of horses by vaccination. To address this issue, virus variants 
were generated in Shetland ponies. For this study, the cell culture 
adapted Wyoming strain of EIAV (98) was used at its second passage in 
Shetland ponies to infect a series of third passage recipients. EIAV 
isolates obtained from these ponies during febrile episodes were charac­
terized by serological and biochemical methods.
The following is an outline of the research objectives:
1. Generate a panel of EIAV variants in Shetland ponies.
a. Isolate EIAV from acute-phase plasma by end-point dilution in 
fetal equine kidney cell cultures.
b. Characterize the virus isolates in cross-neutralization assays using
a panel of EIA convalescent sera and rabbit hyperimmune sera
against lentil-lectin affinity purified EIAV glycoproteins.
c. Analyze these viral isolates in Western immunoblots and
using a panel of MAbs and convalescent antisera.
d. Analyze viral glycoproteins by two-dimensional tryptic-
peptide mapping.
Isolate neutralization escape mutants using neutralizing convalescent
sera. Analyze these mutants in:
a. Western blot using convalescent sera and MAbs.
b. Neutralization by heterologous convalescent sera and the 
glycoprotein specific antisera.
Document the kinetics of anti-EIAV humoral responses during
persistent infection.
Evaluate a single-step immunoblot assay for EIAV antibody and
antigen detection, respectively.
REFERENCES CITED
ADA, G. G, JONES, P. D.: The immune response to influenza 
infection. Curr. Top. Microbiol. Immunol. 128,1-54 (1986).
ADRI, A. M., THORMAS, RAF-VRUSEN, ALBERT, B.: Relationship 
between poliovirus neutralization and aggregation. J. Virol 59, 479- 
485 (1986).
AIR, G. M., LAVER, W. G.: The molecular basis of antigenic 
variation in influenza virus. Adv. Virus Res. 31, 53-103 (1986).
ALIZON, M., WAIN-HOBSON, L., MONTAGNIER, L., SONIGO, P.: 
Genetic variability of the AIDS virus: nucleotide sequence analysis 
of two isolates from African patients. Cell 46, 63-74 (1986).
ANDERSON L. W., KLEVJER-ANDERSON, P., LIGGITT, H. P.: 
Susceptibility of blood-derived monocytes and macrophages to 
caprine arthritis-encephalitis virus. Infect. Immun. 41, 437-840
(1983).
ARCHER, B. G., CRAWFORD, T. B., MCGUIRE, T. C., FRAZIER, M.
E.: RNA-dependent DNA polymerase associated with equine
infectious anemia virus. J. Virol. 22,16-22 (1977).
ASJO, B., IVHED, I., GIDLUND, M., FUERSTENBERG, S., FENYO, E. 
M., NILSSON, K., WIGZELL, H.: Susceptibility to infection by the 
AIDS virus correlates with T4 expression in monocytoid cell lines. 
Virology 157,359-365 (1987).
AUGUST, J. T., BOLOGNESI, D. P., FLEISSNER, E., GILDEN, R. V., 
NOWINSKI, R. C.: A proposed nomenclature for the virion proteins 
of oncogenic RNA viruses. Virology 60,595-601 (1974).
9. BARNETT, D.: Heat inactivation of equine infectious anemia virus in 
equine serum. Proc. 76th U.S. Anim. Hlth Assoc. Mtg pp. 231-236 
(1972).
10. BARRE-SINOUSSI, F., CHERMAN, J. C , REY, F., NUGEYRE, M. T., 
CHAMARET, S., GRUEST, J., DAUGUET, C. AXLERBLIN, C., 
VEZINET-BRUN, F., ROUZIOUX, C., ROZENBAUM, W., 
MONTAGNIER, L.: Isolation of a T-lymphotropic retrovirus from a 
patient at risk for acquired immune deficiency syndrome (AIDS). 
Science 220,868-871 (1983).
11. BOUILLANT, A. M. P., BECKER, S. A. W. E.: Ultrastructural
comparison of oncovirinae (Type C), spumavirinae and lentivirinae: 
Three subfamilies of retroviridae found in farm animals. J. Nat.
Cancer Inst. 72,1075-1084 (1984).
12. BORST, P. CROSS, G. A. M.: Molecular basis of trypanosome
antigenic variation. Cell, 29, 291-303 (1982).
13. BOTH, G. W., SLEIGH, M. J., COX, N. J. KENDAL, A. P. Antigenic 
drift in influenza virus H3 hemagglutinin from 1968 to 1980: 
Multiple evolutionary pathways and sequential amino acid changes 
at key antigenic sites. J. Virol. 48,52-60 (1983).
14. CASAREALE, D. C., STEVENSON, M., SAKAI, K., VOLSKY, D. J.: A 
human T-cell line resistant to cytopathic effects of the Human 
immunodeficiency virus (HIV). Virology 156,40-49 (1987).
15. CHARMAN, H. P., BLADEN, S., GILDEN, R. V., COGGINS, L.: 
Equine Infectious Anemia Virus: Evidence favoring classification as 
a retrovirus. J. Virol. 19,1073-1079 (1976).
16. CHEEVERS, W. P., ARCHER, B. G., CRAWFORD, T. B.: Charact­
erization of RNA from equine infectious anemia virus. J. Virol. 24, 
489-497 (1977).
17. CHEEVERS, W. P., WATSON, S. G., KLEVJER-ANDERSON, P.: 
Persistent infection by Equine infectious anemina virus: Asymmetry 
of nucleotide sequence reiteration in the integrated provirus of 
persistently infected cells. Virology 118,246-253 (1982).
18. CHEEVERS, W. P. McGUIRE, T. C.: Equine Infectious Anemia Virus: 
Immunopathogenesis and persistence. Rev. Infect. Dis. 7(1), 83-88
(1985).
19. CHEN, I. S. Y.: Regulation of AIDS virus expression. Cell 47, 1-2
(1986).
20. CHIU, I. M., YANIV, A., DAHLBERG, J. E., GAZIT, A., SKUNTZ, S.
F., TRONICK, S. R., AARONSON, A.: Nucleotide sequence evidence 
for relationship of AIDS retrovirus to Lentiviruses. Nature 317, 366- 
368 (1985).
21. CLAPHAM, P. R., WEISS, R. A., DALGLEISH, A. G., EXLEY, M„
WHITBY, D. HOGG, N.: Human immunodeficiency virus infection of 
monocytoid and T-lymphocytic cells: Receptor modulation and
differentiation induced by phorbol ester. Virology 158,44-51 (1987)
22. CLAVEL, F., KLATZMANN, D. MONTAGNIER, L.: Deficient LAV-1 
neutralizing capacity of sera from patients with AIDS or related 
syndromes. Lancet 1,879-880 (1985).
23. CLAVEL, F., GUETARD, D., BRUN-VEZINET, F., CHAMARET, S., 
REY, M. A., SANTOS-FERREIRA, M. O., LAURENT, A. G., DAN- 
GUET, C , KATLAMA, C., ROUZIOUX, C., KLATZMANN, D., 
CHAMPALIMUD, J. L., MONTAGNIER, L.: Isolation of a new human
24.
• 25. 
26.
27.
28.
29.
30.
31.
30
retrovirus from West Africa patients with AIDS. Science 233, 343- 
346 (1985).
CLEMENTS, J. E., PEDERSEN, F. S., NARAYAN, O., HASELTINE, W. 
A.: Genomic changes associated with antigenic variation of visna 
virus during persistent infection. Proc. Natl. Acad. Sci. U.S.A 77, 
4454-4458 (1980).
CO, M. S., FIELDS, B. N., GREENE, M. I.: Viral receptors serving 
host functions, pp.126-131. In Concepts in Viral Pathogenesis, Vol 2. 
Springer-Verlag, NY (1986).
COFFINS, J., HAASE, J. A., LEVY, A., MONTAGNIER, L., 
OROSZLAM, S., TEICH, N., TEMIN, H., TOYOSHINIA, K., VARMUS, 
H. VOGT, P., WEISS, R.A.: What to call the AIDS virus? Nature 
321,10 (1986).
COFFIN, J.: Structure of the retroviral genome, pg 261-368. In 
Molecular Biology of Tumor Viruses: RNA Tumor viruses. 2nd 
Edition, Weiss, R., Teich, N., Varmus, H., and Coffin, J. Cold Spring 
Harbor Laboratory, Cold Spring Harbor, NY (1984).
COGGINS, L. NORCROSS, N. L.: Immunodiffusion reaction in equine 
infectious anemia. Cornell Vet. 60,330-335 (1970).
COGGINS, L., NORCROSS, N. L. NAUSTRAUM, S. R.: Diagnosis of 
equine infectious anemia by immunodiffusion test. Am. J. Vet. Res. 
33,11-18 (1972).
COGGINS, L.: Mechanism of viral persistence in equine infectious 
anemia. Cornell Vet. 65,143-151 (1972).
COGGINS, L., KEMEN, M. J.: Inapparent carriers of equine 
infectious anemia (EIA) virus. Equine infectious anemia workshop
proceedings, 14-22. 4th Int. Conf. on Equine Infectious Diseases,
Ky, Grayson Foundation, 1976.
32. COGGINS, L. MATHEKA, H. P., CHARMAN, H. P.: Radioimmunoassay 
for equine infectious anemia virus antigen and antibody. J. Eq. Med. 
Surg. 1,351-358 (1978).
33. COHEN, G. H., DIETZSCHOLD, B., PONCE DE LEON, M., LONG, D.,
GOLUB, E., VARRICHIO, A., PEREIRA, L., EISENBERG, R.: 
Localization and synthesis of an antigenic determinant of herpes
simplex virus glycoprotein D that stimulates production of 
neutralizing antibody. J. Virol. 49,102 (1984).
34. CORK, L. C., HADLOW, W. J., CRAWFORD, T. B., GORHAM, J. R.
PIPER, R.C.: Infectious leukoencephalomyletis of young goats. J
Infect. Dis. 129,134-141 (1974).
35. CRAWFORD, T. B., MCGUIRE, T. C., HENSON, J. B.: Detection of
equine infectious anemia in vitro by immunofluorescence. Arch.
Virol. 34,332-339 (1971).
36. CRAWFORD, T. B., CHEEVERS, W. P., KLEVJER-ANDERSON, P.,
MCGUIRE, T.C.: Equine Infectious Anemia: Virion characteristics,
virus-cell interaction and host responses. In Persistent Viruses, pp.
727-749. ICN-UCLA Symposium on Molecular and Cellular Biology, 
vol, 2. Stevens, J., Todaro, G. and Fox, C.F. ( eds), Academic Press, 
NY (1978).
37. CROWELL, R. L., HSU, K-H, L.: Isolation of cellular receptors, pp.
117-125. In Concepts in Viral Pathogenesis vol 2. Springer-Verlag,
NY (1986).
38. DALGLEISH, A. G., BEVERLERY, P. L. C., CLAPHAM, P. R.,
CRAWFORD, D. H., GREAVES, M. F., WEISS, R. A.: The CD4 (T4) 
antigen is an essential component of the receptor for the AIDS 
retrovirus. Nature 312,763-767 (1984).
39. DANIEL, M. D., KING, N. W., LEVTIN, N. L., HUNT, R. D., 
SEGHAL, P. K., DESROSIERS, R. C.: A new type D retrovirus 
isolated from macaques with immune-deficiency syndrome. Science 
227,177-181 (1984).
40. De BOER, G. F.,: Zwoegerziekte virus, the causative agent for 
progressive interstitial pneumonia (maedi) and meningo- 
leukoencephalitis (visna) in sheep. Vet. Res. 18,15-25 (1975).
41. DIAMOND, C. D., JAMESON, B. A., BONIN, J., KOHARA, M., ABE, 
S., ITOH, H., KOMATSU, T., ARITA, M., KUGE, S., NOMOTO, A., 
OSTERHAUS, A. D. M. E., CRAINIC, R., WIMMER, E.: Antigenic 
variation and resistance to neutralization in poliovirus type 1. 
Science 229,1090-1093 (1985).
42. DICKSON, C„ EISENMAN, R., FAN, H., HUNTER, E., TEICH, N.: pg 
513-648. In Molecular Biology of Tumor Viruses: RNA Tumor 
viruses. 2nd Edition, Weiss, R., Teich, 'N., Varmus, H., and Coffin, J. 
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984)
43. DIMMOCK, N. J.: Mechanisms of neutralization of animal viruses.' J. 
Gen. Virol. 65,1015-1022 (1984).
44. EMINI, E. A., KAO, S. Y., LEWIS, A. J., CRAINIC, R., WIMMER, E.: 
Functional basis of poliovirus neutralization determined with 
monospecific neutralizing antibodies. J. Virol. 46,466-474 (1983a).
45. EMINI, E. A , OSTAPCHUK, P., WIMMER, E.: Bivalent attachment 
of antibody onto poliovirus leads to conformational alteration and
neutralization. J. Virol. 48,157 (1983b).
46. EVANS, L. A., MCHUGH, T. M., STTCES, D. P., LEVY, J. A.: 
Differential ability of human immunodeficiency virus isolates to 
productively infect human cells. J. Immunol. 138,3415-3418 (1987).
47. FENNER, F.: The classification and nomenclature of viruses.
Intervirology 6,1-12 (1975).
48. FOLKS, T., POWELL, D., LIGHTFOOTE, M. M., BENN, S., MARTIN, 
M. A., FAUCI, A. S.: Induction of HTLV-3/LAV from a nonvirus 
producing T-cell line: Implications for latency. Science 231, 600-602
(1986).
49. GARTNER, S., MARKOVITS, P., MARKOVITS, D. M., KAPLAN, M. 
H., GALLO, R. C., POPOVIC, M.: The role of mononuclear 
phagocytes in HTLV-3/LAV infection. Science 233,215-219(1986).
50. GELDERBLOM, H. R., HAUSMANN, E. H. S., OZEL, M., PAULI, G., 
KOCH, M. A.: Fine structure of Human immunodeficiency virus 
(HIV) and immunolocalization of structural proteins. Virology 156, 
171-176 (1987).
51. GENDELMAN, H. E., NARAYAN, O., MOLINEAUX, S., CLEMENTS, J. 
E. GHOTIB, Z.: Slow, persistent replication of lentiviruses: Role of 
tissue macrophages and macrophage precursors in bone marrow. 
Proc. Natl. Acad. Sci. U.S.A 82,7086-7090 (1985).
52. GENDELMAN, H. E., NARAYAN, O., KENNEDY-STOSKOPF, S., 
KENNEDY, P. G. E., GHOTIB, Z., CLEMENTS, J. E., STANELY, J., 
PEZESHKAPOUR, G.: Tropism of sheep lentiviruses for monocytes: 
Susceptibility to infection and virus gene expression increase during 
maturation of monocytes to macrophages. J. Virol. 58,67-74 (1986).
53. GERHERD, W., WEBSTER, R. G.: Antigenic drift in influenza A 
viruses. 1. Selection and characterization of antigenic variants of 
A /PR /8/34 (H0N1) influenza virus with monoclonal antibodies. J. 
Exp. Med. 148,383-392 (1978).
54. GOLDSTEIN, J. L., BROWN, M. S., ANDERSON, R. G. W., RUSSELL, 
D. W., SCHNEIDER, W. J.: Receptor-mediated endocytosis: concepts 
emerging from the LDL receptor system. Ann. Rev. Cell Biol. 1, 1- 
39 (1985).
55. GOLLINS, S. W., PORTERFIELD, J. S.: A new mechanism for the 
neutralization of enveloped viruses by antiviral antibody. Nature 
321, 244-246 (1986).
56. GONDA, M. A., CHARMAN, H. P., WALKER, J. L., COGGINS, L.: 
Scanning electron microscopy study of EIAV. Am. J. Vet. Res. 39, 
431-440 (1978).
57. GONDA, M. A., WONG-STAAL, F., GALLO, R. C., CLEMENTS, J. E„ 
NARAYAN, O., GELDEN, R. V.: Sequence homology and morphologic 
similarity of HTLV-3 and visna virus, a pathogenic lentivirus. 
Science 227,173-177 (1985).
58. GYORKEY, F., MELNICK, J., SINKOVICS, J., GYORKEY, P.: 
Retrovirus resembling HTLV-3 in macrophages of patients with 
AIDS. Lancet 1,106 (1985).
59. GUDNADOTTIR, M. PALSSON, P.: Transmission of maedi by 
inoculation of a virus grown in tissue culture from maedi-affected 
lungs. J. Inf. Dis. 117,1-6 (1967).
60. GUYADER, M. EMERMAN, M., SONIGO, P., CLAVEL, F„
MONTAGNIER, L., ALIZON, M.: Genome organization and
transactivation of the human immunodeficiency virus type 2. Nature 
326, 662-669 (1987)
61. HAASE, A. T.: The slow infection caused by visna virus. Curr. Top. 
Microbiol. Immunol. 72,101-156 (1975).
62. HAASE, A. T.: Pathogenesis of lentivirus infections. Nature 322, 
130-136 (1986).
63. HAHN, B. H., GONDA. M., SHAW, G. M., POPOVIC, M., HOXIE, J., 
GALLO, R. C. WONG-STAAL, F.: Genomic diversity of the AIDS 
virus HTLV-3: different viruses exhibit greatest diversity in their 
envelope genes. Proc. Natl. Acad. Sci. U.S.A 82,4813-4817 (1985).
64. HAHN, B. H., SHAW, G. M., TAYLOR, M. E., REDFIELD, R. R„
MARKHAM, P. D., SALAHUDDIN, S. Z., WONG-STAAL, F., GALLO, 
R. C., PARKS, E. S., PARKS, W. P.: Genetic variation in HTLV-
3/LAV over time in patients with AIDS or at risk for AIDS.
Science 232,1548-1554 (1986).
65. HARRIS, J. D., BLUM, H. B., SCOTT, J., TRAYNOR, B., VENTURA,
P., HAASE, A.: Slow virus visna: Reproduction in vitro of virus
from extrachromosomal DNA. Proc. Natl. Acad. Sci. U. S. A. 81,
7212-7215 (1984).
66. HAWKINS, J. A., ADAMS, W. V. Jr., WILSON, B. H., ISSEL, C. J., 
ROTH, E. E.: Transmission of equine infectious anemia virus by 
Tabanus fuscicostatus. Am. J. Vet. Med. Ass. 168, 63-64.
67. HENSON, J. B., McGUIRE, T. C.: Immunopathology of equine 
infectious anemia. Am. J. Clin. Path. 56,306-314 (1971).
68. HENSON, J. B., McGUIRE, T. C.: Equine infectious anemia. Prog. 
Med. Virol. 18,143-159 (1974).
69. HOLLAND, J., SPINDLER, K., HORODYSKI, F., GRABAU, E., 
NICHOL, S., VANDEPOL, S.: Rapid evolution of RNA genomes. 
Science 215,1577-1585 (1982).
70. HOLLAND, T. G, MARLIN, S. D., LEVINE, M., GLORIOSO, J.: 
Antigenic variants of herpes simplex virus selected with 
glycoprotein-specific monoclonal antibodies. J. Virol. 45, 672-682
(1983).
71. HOLLAND, J. J.: Continuum of change in RNA virus genomes. In 
Concepts in viral pathogenesis. Edited by Abner Louis Notkins and 
Michael B.A. Oldstone. Springer-Verlag New York Inc. pp. 137-143
(1984).
72. HOXIE, J. A., HAGGARTY, B. S., RACKOWSKI, J. L., PILLSBURY, 
N., LEVY, J. A.: Persistent noncytopathic infection of normal human 
T lymphocytes with AIDS-Associated Retrovirus. Science 229, 1400- 
1402 (1985).
73. HULL, R., COVEY, S. N.: Genome organization and expression of 
reverse transcribing elements: Variation and a Theme. J. Gen. 
Virol. 67,1751-1758 (1986).
74. HUSSAIN, K. A., ISSEL, C. J., SCHNORR, K. L., RWAMBO, P. M„ 
MONTELARO, R. C.: Antigenic analysis of equine infectious anemia 
virus (EIAV) variants using monoclonal antibodies: epitopes of 
glycoprotein 90 (gp90) of EIAV stimulate neutralizing antibodies. J. 
Virol. 61,2956-2961 (1987).
75. HYSLOP, N. S. G.: Isolation of variant strains of foot-and-mouth 
disease virus propagated in cell cultures containing antiviral sera. 
J. Gen. Microbiol. 4,135 (1965).
76. ICENOGLE, J., SHIWEN, H., DUKE, G., GILBERT, S., RUECKERT, 
R., ANDEREGG, J.: Neuralization of poliovirus by monoclonal 
antibody: kinetics and stoichiometry. Virology 127,412-425 (1983).
77. ISSEL, C. J., COGGINS, L.: Equine infectious anemia: Current 
knowledge. Am. J. Vet. Med. Ass. 174,727-733 (1979).
78. ISSEL, C. J., ADAMS, W. V. Jr.: Serologic survey for equine 
infectious anemia virus in Louisiana. Ame. J. Vet. Med. Ass. 174, 
286-288 (1979).
79. ISSEL, C. J., FOIL, L. D.: Studies on equine infectious anemia virus 
transmission by insects. Ame. Vet. Med. Ass. 184 (3), 293-297 
(1984).
80. KANKI, P. J., ALROY, J., ESSEX, M.: Isolation of T-lymphotropic 
retrovirus related to HTLV-3/LAV from wild-caught African green 
monkeys. Science 230, 951-954 (1985).
81. KEMEN, M. J. Jr., COGGINS, L.: Equine infectious anemia: 
Transmission from infected mares to foals. Ame. J. Vet. Med. Ass. 
161,496-499 (1972).
82. KEMENY, L., MOTT, L., PEARSON, J.: Titration of equine infectious 
anemia virus. Effect of dosage on incubation time and clinical signs. 
Cornell Vet. 61,688-695 (1971).
83. KENNEDY, R. C., EKLUND, C. M., LOPEZ, C., HADLOW, W. J.: 
Isolation of virus from lungs of Montana sheep affected with 
progressive pnuemonia. Virology, 35,483-484 (1968).
84. KENNEDY-STOSKOPF, S., NARAYAN, O.: Neutralizing antibody to
visna virus: mechanism of action and possible role in virus
persistence. J. Virol. 59,37-44 (1986).
85. KLATZMANN, D„ BARRE-SINOUSSI, F., NUGEYRE, M. T., 
DAUGUET, C., VILMER, E., GRISCELLI, C., ROUZIOUX, C„ 
GLUCKMAN, J. C., MONTAGNffiR, L.: Selective tropism of 
lymhadenopathy associated virus (LAV) for helper-inducer T 
lymphocytes. Science 225,59-63 (1984).
86. KOENIG, S., GENDELMAN, H. E., ORENSTEIN, J. M. DAL CANTO, 
M. C., PEZESHKPOUR, G. H., YUNGBLUTH, M., JANOTTA, F„ 
ASKSAMIT A., MARTIN, M. A., FAUCI, A. S.: Detection, of AIDS 
virus in macrophages in brain tissue from patients with 
encephalopathy. Science 233,1089-1093 (1986)
87. KONO, Y.: Viremia and immunological responses in horses infected 
with equine infectious anemia virus. Natl. Inst. Anim. Hlth. Quart. 
(Tokyo) 8,1-9 (1969).
88. KONO, Y., YOSHINO, T., FUKUNAGA, Y.: Growth characteristics 
of equine infectious anemia virus in horse leukocyte cultures. Arch. 
Virol. 30,252-256 (1970).
89. KONO, Y., KOBAYASHI, K., FUKUNAGA, Y.: Serological comparison 
among various strains of equine infectious anemia virus. Arch. 
Virol. 34, 202-208 (1971).
90. KONO, Y., KOBAYASHI, K., FUKUNAGA, Y.: Antigenic drift of 
equine infectious anemia virus in chronically infected horses. Arch. 
Virol. 41,1-10 (1973).
91. KONO, Y.: Reccurences of equine infectious anemia. Approaches to 
understanding of the mechanisms. In Proc. 3rd Int. Conf. Equine 
Infectious Diseases, pp. 175-186. Basel: S. Karger (1973).
92. KONO, J., HIRASAWA, K , FUKUNAGA, Y., TANIGUCHI, T.
39
Recrudescence of equine infectious anemia by treatment with 
immunosuppressive drugs. Natl. Inst. Anim. Hlth. Quart. 16, 8-15.
93. KOYANAGI, Y., MILES, S., MITSUYASU, R. T., MERRILL, J. E., 
VINTERS, H. V., CHEN, I. S. Y.: Dual infection of the central 
nervous system by AIDS viruses with distinct cellular tropisms. 
Science 236,819-822 (1987).
94. LEE, P. W. K., HAYES, E. G, JOKLIK, W. C.: Protein s i is the 
reovirus attachment protein. Virology 108,156-163 (1981).
95. LEVY, J. A., SHIMABUKURO, J., MCHUGH, T., CASAVANT, C., 
STTTES, D., OSHIRO, L.: AIDS-associated retrovirus (ARV) can 
productively infect other cells besides human T helper cells. 
Virology 147, 441-448 (1985).
96. LEVY, A. L., CHENG-MAYER, C., DINA, D., LUCIW, P. A. AIDS 
retrovirus (ARV-2) clone replicates in transfected human and animal 
fibroblasts. Science 232, 998-1001 (1986).
97. LUTLEY, R., PETURSSON, G., PALSSON, P. A., GEORGSSON, G., 
KLEIN, J., NATHANSON, N.: Antigenic drift in visna virus: virus 
variation during long term infection of Icelandic sheep. J. Gen. 
Virol. 64,1433-1440 (1983).
98. MALMQUIST, W. A., BARNETTE, D., BECVAR, C. S.: Production of 
equine infectious anemia virus antigen in a persistently infected 
cell line. Arch. Virol. 42,361-370 (1973).
99. MANDEL, B.: Neuralization of poliovirus: a hypothesis to explain 
the mechanism and one-hit character of the neutralization reaction. 
Virology 69,500-510 (1976).
100. MANDEL, B.: Interaction of viruses with neutralizing antibodies. In
Comprehensive Virology, vol. 15, pp. 37-121. Edited by H. Fraenkel- 
Conrat & R. R. Wagner. New York: Plenium Press (1979).
101. MANDEL, B.: Mechanism of virus neutralization. In Concepts in 
viral pathogenesis. Edited by Abner Louis Notkins and Michael B.A. 
Oldstone. Springer-Verlag New York Inc. pp. 32-38 (1984).
102. MATHEKA, H. D., COGGINS, L., SHIVELY, J. N., NORCROSS, N. L.:
Purification and characterization of equine infectious anemia virus.
Arch. Virol. 51,107-114 (1976).
103. MATHEWS, T. J., LANGOS, A. J., ROBEY, W. G., CHANG, N. T.,
GALLO, R. C., FISCHINGER, P. J., BOLOGNESI, D. P.: Restricted
neutralization of divergent human T-lymphotropic virus type-3 
isolates by antibodies to the major envelope glycoprotein. Proc. 
Natl. Acad. Sci. U. S. A. 83, 9707-9713 (1986).
104. McCULLOUGH, K. C.: Monoclonal antibodies: Implications for 
virology. Arch. Virol. 87,1-36 (1986).
105. McDOUGAL, J. S., KENNEDY, M. S., SLIGH, J. M., CORT, S. P., 
MAWLE, A., NICHOLSON, J. K. A.: Binding of HTLV-3/LAV to T4+ 
T-cells by a complex of the llOkD viral protein and the T4 
molecule. Science 231,382-385 (1986).
106. McGUIRE, T. C., CRAWFORD, T. B., HENSON, J. B.: Immunofl- 
uorescent localization of equine infectious anemia virus in tissues. 
Arne. J. Path. 62,283-292 (1971).
107. McGUIRE, T. C., HENSON, J.: Equine infectious anemia:
Pathogenesis of persistent viral infection. Perspectives in Virology 
8,229-247 (1973).
108. McGUIRE, T. C., CRAWFORD, T. B.: Immunology of a persistent
41
retrovirus infection: Equine infectious anemia. Adv. Vet. Sci. Comp. 
Med. 23,137-159 (1979).
109. MONTAGNIER, L„ DAUGUET,C., AXLER, C., CHAMARET, S., 
NUGEYRE, M.T., REY, F., BARRE-SINOUSSI, F., CHERMANN, J.C.: 
A new type of retrovirus isolated from patients presenting with 
lymphandenopathy and acquired immune deficiency syndrome: 
structural and antigenic relatedness with equine infectious anemia 
virus. Annales de Virologie 135E, 119-134 (1984).
110. MONTAGNIER, L„ GRUEST, J., CHAMARET, S., DAGUET, C„ 
AXLER, C , GUETARD, D., NUGEYRE, M. T., BARRE-SINOUSSI, F., 
CHERMANN, J. C., BRUNET, J. B., KLATZMANN, D., GLUCKMAN, 
J. C.: Adaptation of lymphadenopathy virus (LAV) to replication in 
EBV-transformed B lymphoblastoid cell lines. Science 225, 63-66
(1984).
111. MONTELARO, R.C., BOLOGNESI, D. P.: Structure and morphogenesis 
of type-C retroviruses. Adv. Cancer Res. 28, 63-69 (1978).
112. MONTELARO, R. C., LOHREY, N., PAREKH, B., BLAKENEY, E. W., 
ISSEL, C.J.: Isolation and comparative biochemical properties of the 
major internal polypeptides of equine infectious anemia virus. J. 
Virol. 42,1029-1038 (9182).
113. MONTELARO, R. C , PAREKH, B., ORREGO, A., ISSEL, C. J.: 
Antigenic variation during persistent infection by equine infectious 
anemia virus, a retrovirus. J. Biol. Chem. 259,10539-10544 (1984).
114. NAKAJIMA, H.: Physicochemical and biological characterization of 
equine infectious anemia virus, pp. 162-174. In Proc. 3rd Int. Conf. 
Equine Infectious Dis., Paris (1972) (Karger, Basel 1973)
115.
116.
117.
118.
119.
120. 
121.
42
NARAYAN, O., GRIFFIN, D. E., CHASE, J.: Antigenic drift of visna 
virus in persistently infected sheep. Science 197,376-378 (1977). 
NARAYAN, O., WOUNSKY, J. A., CLEMENTS, J. E., STANDBERG, J. 
D., GRIFFIN, D. E., CORK, L. C.: Slow virus replication: The role 
of macrophages in the persistence and expression of visna viruses 
of sheep and goats. J. Gen. Virol. 59,345-356 (1982).
NARAYAN, O., KENNEDY-STOSKOPF, S., SHEFFER, D., GRIFFIN, 
D. E., CLEMENTS, J. E.: Activation of caprine arthritis-encephalitis 
virus expression during maturation of monocytes to macrophages. 
Infect. Immun. 41, 67-73 (1983).
NARAYAN. O., SHEFFER, D., CLEMENTS, J. E., TENNEKOON, G. 
Restricted replication of lentiviruses: Visna virus induce a unique 
interferon during interaction between lymphocytes and infected 
macrophages. J. Exp. Med. 162,1954-1969 (1985).
NICHOLSON, J. K. A., CROSS, G. D., CALLAWAY, C. S., 
McDOUGAL, J. S.: In vitro infection of human monocytes with 
human T lymphotropic virus type 3/lymphadenopathy-associated 
virus (HTLV-3/LAV). J. Immunol. 137,323-329 (1986).
NORRBY, E.: Immunogenecity of vaccine products and neutralizing 
antibodies, pp. 346-353. In Concepts in Viral Pathogenesis vol 2. 
Springer-Verlag, NY (1986).
NUMBERG, J. H., RODGERS, G., GILBERT, J. H., SNEAD, R. M. 
Method to map antigenic determinants recognized by monoclonal 
antibodies: Localization of a determinant of virus neutralization on 
the feline leukemia virus envelope protein gp-70. Proc. Natl. Acad. 
Sci. U.S.A81,3675(1984).
122. ORREGO, A., ISSEL, C.J., MONTELARO, R.C., ADAMS, W.V. Jr.: 
Virulence and in vitro growth of a cell adapted strain of equine 
infectious anemia virus after serial passage in ponies. Ame. J. Vet. 
Res. 43,1556-1560 (1982).
123. ORREGO, A.: Equine infectious anemia virus. 1. Generation of virus 
variant candidates. 2. Attempts to titrate by three different 
methods. Ph. D. dissertation, Louisiana State University, Baton 
Rouge, LA (1983).
124. PALESE, P.: Reassortment continuum. In Concepts in viral
pathogenesis. In Concepts in viral pathogenesis. Edited by Abner 
Louis Notkins and Michael B.A. Oldstone. Springer-Verlag New 
York Inc. pp. 144-151 (1984).
125. PAREKH, B., ISSEL, C. J., MONTELARO, R. C.: Equine infectious 
anemia virus, a putative lentivirus contains polypeptides analogous 
to prototype-C oncrnaviruses. Virology 107,520-525 (1980).
126. PAYNE, S. L., PAREKH, B., MONTELARO, R. C., ISSEL, C. J.: 
Genomic alterations associated with persistent infections by equine 
infectious anemia virus, a retrovirus. J. Gen. Virol. 65, 1395-1399
(1984).
127. PAYNE, S. L., SALINOVICH, O., NAUMAN, S. M., ISSEL, C. J., 
MONTELARO, R. C.: Course and extent of variation of equine 
infectious anemia virus during parallel persistent infections. J. 
Virol. 61,1266-1270 (1987).
128. PELUSO, R., HAASE, A., STROWRING, L.: A Trojan horse 
mechanism for the spread of visna virus in monocytes. Virology 
147,231-236 (1985).
129. POPOVIC, M., SARGADHARAN, M. G., READ, E., GALLO, R. C.: 
Detection, isolation and continuous production of cytopathic 
retroviruses (HTLV-3) from patients with AIDS and pre-AIDS. 
Science 244, 497-500 (1984).
130. POSSEE, R. D., SCHILD.G. C., DIMMOCK, N. J.: Studies on the 
mechanism of neutralization of influenza virus by antibody: evidence 
that neutralizing antibody (anti-haemagglutinin) inactivates 
influenza virus in vivo by inhibiting virion transcriptase activity. J. 
Gen. Virol. 58, 378-386 (1982).
131. RATNER, L., HASELT1NE, R., LIVAK, P. K., STARCICH, B., 
JOSEPHS, S., DORAN, R. E., RAFALSKI, J. A., WHITEHORN, E. A., 
BAUMEISTER, K., IVANOFF, L., PETTEWAY, S. R., 
LAUTENBERGER, I. A., PAPAS, T. S., GHRAYEB, J., CHANG, J., 
GALLO, R. C., WONG-STAAL, F.: Complete nucleotide sequence of 
the AIDS virus, HTLV-3. Nature 313,277-284 (1985).
132. RE ANNE Y, D. C.: The evolution of RNA viruses. Annual Rev. 
Microbiol. 36,47-73 (1982).
133. RICE, N. R., SIMEK, S., RYDER, O. A., COGGINS, L.: Detection of 
proviral DNA in horse cells infected with equine infectious anemia 
virus. Journal of Virology 26,577-583 (1978).
134. ROGERS, G. N., PAULSON, J. C., DANIELS, R. S., SKEHEL, J. J., 
WILSON, I. A., WILEY, D. C.: Single amino acid substitutions in 
influenza hemagglutinin change receptor bindning specificity. Nature 
340, 76-78 (1983).
135. RUSHLOW, K., OLSEN, K., STIEGLER, G., PAYNE, S. L., 
MONTELARO, R. C., ISSEL, C. J.: Lentivirus genomic organization:
45
The complete nucleotide sequence of the env gene of equine 
infectious anemia virus. Virology 155,309-321 (1986).
136. SALINOVICH, O., PAYNE, S.L., MONTELARO, R. C., HUSSAIN, K.
A., ISSEL, C. J., SCHNORR, K. L.: Rapid emergence of novel 
antigenic and genomic variants of equine infectious anemia virus 
during persistent infection. J. Virol. 57,71-80 (1986).
137. SCHNEIDER, J., KAADEN, O., COPELAND, T. D., OROSZLAN, S., 
HUNSMANN, G.: Shedding and interspecies type sero-reactivity of 
the envelope glycoprotein gp-120 of the human immunodeficiency 
virus. J. Gen. Virol. 67,2533-2538 (1986).
138. SCOTT, J. V., STOWRING, L., HAASE, A., NARAYAN, O., VIGNE, 
R.: Antigenic variation in visna virus. Cell 18,321-327 (1979).
139. SENTSUI, H., KONO, Y.: Hemagglutination by equine infectious 
anemia virus. Infect. Immun. 14,325-331 (1976).
140. SHANE, B. S., ISSEL, C. J., MONTELARO, R. C.: Enzyme-linked 
immunosorbent assay for the detection of equine infectious anemia 
p26 antigen and antibody. J. Gen. Microbiol. 19,351-355 (1984).
141. SHARPE, A. H., FIELDS, B. N.: Pathogenesis of viral infections. 
Basic concepts derived from the reovirus model. New Eng. J. Med. 
312,486-497 (1985).
142. SHAW, G. M., HAHN, B. H., ARYA, S. K., GROOPMAN, J. E., 
GALLO, R.C., WONG-STAAL, F.: Molecular characterization of 
human T-cell leukemia (lymphotropic) virus type 3 in the acquired 
immune deficiency syndrome. Science 226,1165-1171 (1984).
143. SHAW, G. M., HARPER, M. E., HAHN, B. H., EPSTEIN, L. G., GAJ- 
DUSEK, D. C., PRICE, R. W., NAVIA, B. A., PETITO, C. K., O’HA-
144.
145.
146.
147.
148.
149.
150.
46
RA,C. J.,GROOPMAN, J. E., CHO, E. S., OLESKE, J. M., WONG- 
STAAL, F., GALLO, R. C.: HTLV-3 infection in brains of children 
and adults with AIDS encephalopathy. Science 227,177-182 (1984).
SHEN, D., CRAWFORD, T. B., GORHAM, J. R., McGUIRE, T. C.: 
Inactivation of equine infectious anemia virus by chemical 
disinfectants. Ame. J. Vet..Res. 38(8), 1217-1219 (1977).
SHEN, D. T., GORHAM, J. R., JONES, R. H., CRAWFORD, T. B.: 
Failure to propagate equine infectious anemia virus in mosquitoes 
and Culicoides variipennis. Ame. J. Vet. Res. 39, 875-876 (1978).
SKEHEL, J. J., DANIELS, D. S., DOUGLAS, A. R., WILEY, D. C.: 
Antigenic and amino acid sequence variations in the hemagglutinin 
of type A influenza viruses recently isolated from human subjects. 
Bullettin W .H .0 .61, 671-676 (1983).
STARCICH, B., HAHN, B. H., SHAW, G. M., MCNEELY, P., 
MODROW, S., WOLF, H., PARKS, E. S., PARKS, W. P., JOSEPHS, S., 
GALLO, R. C., WONG-STAAL, F.: Identification and characterization 
of conserved and variable regions in the envelope gene of 
HTLV/LAV, the retrovirus of AIDS. Cell 45,637-648 (1986).
STEPHENS, R. M., CASEY, J. W., RICE, N. R.: Equine infectious 
anemia virus gag and pol genes: Relatedness to visna virus and 
AIDS virus. Science 231,589-594 (1986).
STROOP, W. G., BARINGER, J. R. Persistent, slow and latent viral 
infections. Prog. Med. Virol. 28,1-43 (1982).
TARDIEU, M., EPSTEIN, R. L., WEINER, H. L.: Interaction of 
viruses with cell surface receptors. Int. Rev. Cytol. 80, 27-61 
(1982).
151. TAYLOR, H. P., DIMMOCK, N. J.: Mechanisms of neutralization of 
influenza virus by IgM. J. Gen. Virol. 66,903-907 (1985).
152. TAYLOR, H. P., DIMMOCK, N. J.: Mechanisms of neutralization of 
influenza virus by secretory IgA is different from that of 
monomeric IgA or IgG. J. Exp. Med. 161,198-209 (1985).
153. THORMAR, H., BARSHATZKY, M. R., KOZLOWSKI, P. B.: The 
emergence of antigenic variation ia a rare event in long term visna 
virus infection in vivo. J. Gen. Virol. 64,1427-1432 (1983).
154. TEICH, N.: Taxanomy of retroviruses, pp. 25-207. In Molecular 
Biology of Tumor Viruses: RNA Tumor viruses. 2nd Edition, Weiss, 
R., Teich, N., Varmus, H., and Coffin, J. Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY (1984).
155. VARMUS, H., SWANSTROM, R.: Replication of retroviruses, pp. 369- 
512. In Molecular Biology of Tumor Viruses: RNA Tumor viruses. 
2nd Edition, Weiss, R., Teich, N., Varmus, H., and Coffin, J. Cold 
Spring Harbor Laboratory, Cold Spring Harbor, NY (1984).
156. VIRELIZIER, J. L.: Host defenses against influenza virus: the role 
of anti-hemagglutinin antibody. J. Immunol. 115,434-439 (1975).
157. WEBSTER, R. G., LAVER, W. G.: Determination of the number of 
non-overlapping antigenic areas on HongKong (H3N2) influenza virus 
hemagglutinin with monoclonal antibodies and the selection of 
variants with potential epidemiological significance. Virology 104, 
139-148 (1980).
158. WEILAND, F., MATHEKA, H., COGGINS, L., HARTNER, D.: Electron 
microscopic studies on equine infectious anemia virus (EIAV). Arch. 
Virol. 55,335-340.
159. WEISS R. A., CLAPHAM, P. R., CHEINGSONG-POPOV, R., 
DALGLEISH, A. G., CARNE, C. A., WELLER, I. V. D., TEDDER, R. 
S.: Neutralization of HTLV-3 by sera of AIDS and AIDS-risk 
patients. Nature 316,69-72 (1985).
160. WEISS, R. A., CLAPMAN, P. R., WEBER, J. N., DALGLEISH, A. G.,
LASKY, L. A., BERMAN, P. W.: Variable - and conserved
neutralization antigens of human immunodeficiency virus. Nature 
324,572-575 (1986).
161. WIKTOR, J. J., MACFARLAN, R. I., REAGAN, K. J., DIETZSCHOLD,
B., CURTIS, P. J., WUNNER, W. H., KIENY, M. P., LATHE, R., 
LECOQ, J. P., MACKETT, M., MOSS, B., KOPROWSKI, H.: 
Protection from rabies virus by a vaccinia virus recombinant 
containing the rabies virus glycoprotein gene. Proc. Natl. Acad. Sci. 
U.S.A81, 7194(1984).
162. WILLEY, R. L., RUTLEDGE, R. A., DIASS, S., FOLKS, T., 
THEODORE, T., BUCKLER, C. E., MARTIN, M. A.: Identification of 
conserved and divergent domains within the envelope gene of the 
cquired immunodeficiency syndrome retrovirus. Proc. Natl. Acad. Sci. 
U.S.A. 83,5038-5042 (1986).
163. WONG-STAAL, F., SHAW, G. M., HAHN, B. H., SALAHUDDIN, S. Z., 
POPOVIC, M., MARKHAM, P., REDFIELD, R., GALLO, R. C.: 
Genomic diversity of human T-lymphotropic virus type 3 (HTLV-3). 
Science 229,759-762 (1985).
164. YANIV, A., DAHLBERG, J. E., TRONICK, S. R., CHIU, I. M., 
AARONSON, S.A.: Molecular cloning of integrated caprine arthritis- 
encephalitis virus. Virology 145,340-345 (1985).
165. YANIV, A., DAHLBERG, J. E., GAZIT, A., SHERMAN, L., TRONICK,
S.R., CHIU, I. M., AARONSON, S. A.: Molecular cloning and 
physical characterization of integrated equine infectious anemia 
virus: Molecular and immunologic evidence of its close relationship 
to ovine and caprine lentiviruses. Virology 154,1-8 (1986).
166. YEWDELL, J. W., BENNINK, J. R., SMITH, G. L., MOSS, B.:
Influenza A virus nucleoprotein is a major target antigen for cross­
reactive anti-influenza A virus cytotoxic T  lymphocytes. Proc. Natl. 
Acad. Sci. U. S. A. 82,1785-1789 (1986).
167. YEWDELL, J. W„ CATON, A. J., GERHARD, W.: Selection of
influenza A virus adsorptive mutants by growth in the presence of
a mixture of monoclonal antihemagglutinin antibodies. J. Virol. 57, 
623-628 (1986).
CHAPTER TWO
EQUINE INFECTIOUS ANEMIA VIRUS (EIAV): HUMORAL RESPONSES AND 
ANTIGENIC VARIATION DURING PERSISTENT INFECTION IN PONIES.
SUMMARY
Three Shetland ponies (A, B and C) were inoculated with plasma from 
a pony with clinical signs of equine infectious anemia (EIA) and observed 
for 165 to 440 days. Clinical signs of EIA marked by high fever 
( 39.5°C) lasting 2-4 days were observed 2-3 weeks after infection and 
one to four such episodes occurred in each pony. EIAV was reisolated 
from the plasma of each pony by end-point dilution in fetal equine kidney 
(FEK) cells and a plasma viremia 103-5 TCID50/m l was observed during 
each episode. Cross-neutralization tests with sequential serum samples 
showed that the four viruses isolated from pony A during febrile episodes 
4-5 weeks apart were serologically different. Two-dimensional tryptic 
peptide analyses of the envelope glycoproteins of four isolates from pony 
A revealed additions or deletions between each isolate and its immediate 
predecessor. Western blot analyses of these four isolates including those 
from ponies B and C with a panel of monoclonal antibodies demonstrated 
antigenic variation in both gp90 and gp45. Both conserved and variable 
epitopes were identified in each glycoprotein with greatest variation in 
gp90. Specific IgG directed against determinants of EIAV gp90, gp45 and 
p26 was detectable by AGID and Western blots within one month after 
infection. These antibodies appeared to react with conserved antigenic
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determinants of these proteins as they reacted with homologous and 
heterologous virus isolates alike. The group-specific determinants of gp90 
and gp45 were more antigenic than those of p26. The ability of "early" 
sera to recognize determinants on all EIAV isolates did not correlate with 
their ability to neutralize the infectivity of EIAV. Neutralizing 
antibodies, first detectable within two months, were observed to be 
effective only to viruses isolated prior to serum collection but became 
broadly reactive later in the infection regardless of the number of clinical 
episodes.
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INTRODUCTION
Equine infectious anemia virus (EIAV) a lentivirus that shares 
morphological, serological and genetic similarity with human 
immunodeficiency virus (HIV) (8, 19, 33, 34) causes a lifelong persistent 
infection in horses often characterized by recurrent episodes of high 
fever (3, 12). Major virion envelope glycoproteins present the principal 
targets for immune attack against retroviruses (32). Monoclonal 
antibodies to some epitopes of the major envelope glycoprotein of EIAV, 
gp90, have been shown to neutralize virus infectivity (11). In addition to
their ability as retroviruses to persist in their hosts as integrated
proviruses, the lentiviruses further elude protective immune responses 
because the antigenic structures of the surface glycoproteins change (11, 
22, 30, 31). Biochemical analyses of the env gene of the lentiviruses 
have demonstrated marked variability particularly in the region coding 
for the outer envelope protein (4, 9, 10, 27, 28, 35). The rapid antigenic 
variation common in the lentiviruses suggests that development of 
vaccines for these viruses will be difficult. In EIAV, where genomic 
variations often result in the emergence of antigenic variants that cause 
recurrent febrile episodes (16, 26, 27, 28), the extent of antigenic
variation needs to be determined with the hope that suitable immunogens
can be identified.
To extend our previous studies on the antigenic variation of EIAV, 
seven virus isolates recovered from persistently infected ponies were 
analyzed by cross-neutralization with convalescent sera. To determine 
the changes that occur in EIAV proteins during antigenic variation, the
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envelope glycoproteins of the virus isolates were analyzed in two- 
dimensional tryptic peptide maps, Western blots with homologous and 
heterologous equine sera, and a panel 18 monoclonal antibodies. The 
results document the generation of group- and type-specific antibodies to 
EIAV glycoproteins and extend our previous data indicating that during 
persistent infections the virus undergoes rapid antigenic variation by 
altering the structure of the envelope glycoproteins.
MATERIALS AND METHODS 
Animals and viral challenge: Serial passage of the prototype cell adapted
Wyoming strain of EIAV (18) in Shetland ponies and the isolation of virus 
from plasma has been previously described (23). In this study, plasma 
obtained during the first febrile episode of a second passage recipient 
pony (#82) was used as source of challenge virus (23). This plasma has 
been the source of several well characterized antigenic variants of EIAV 
(11, 27, 28, 31). Briefly, three Shetland ponies F135, P135 and P130 
(subsequently referred to as A, B, and C, respectively) were each 
inoculated intravenously with approximately 104-8 median tissue culture 
infective doses (TCID50) of EIAV in plasma. Rectal temperatures were 
daily recorded for a period ranging from 165 to 440 days post inoculation 
(DPI). Plasma samples obtained during febrile episodes ( 39.5°C) (Figure 
1) were the source of EIAV isolates used in this study.
Virus isolation, production and purification: Isolation of virus from
plasma and propagation were performed in fetal equine kidney (FEK) cell
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cultures using previously described methods (20, 23). The predominant 
virus in each febrile episode was isolated by end-point dilution in FEK 
cell cultures. Production of EIAV antigen in these cells was monitored in 
an agar gel immunodiffusion (AGID) test (1). End-point diluted viruses 
were produced in FEK cell cultures and purified on 20-80% glycerol 
- gradients according to previously described methods (20,24).
Equine convalescent sera: Sera collected from experimentally infected
ponies and naturally infected horses were used to characterize virus 
isolates in neutralization and immunoblot assays. Sera from 
experimentally infected ponies were collected between febrile episodes and 
during the afebrile periods. Sera from naturally infected horses were 
selected from horses known to be infected (by AGID test seropositivity) 
for over 10 years.
Detection of antibodies to EIAV: Antibodies to EIAV were detected in
the agar gel immunodiffusion (AGID) test using approved protocols (29) 
and commercially available reagents (Pittman-Moore, Washington Crossing, 
NJ), in virus neutralization and in immunoblot assays.
Virus neutralization assay: The neutralizing activities of convalescent
sera were determined in FEK cell cultures using the alpha-method of 
virus neutralization. Viruses isolated from plasma were reacted with 
serum collected both before and after each febrile episode. Serial 10-fold 
dilutions of each virus were mixed with a standard dilution (1:4 in MEM) 
of heat inactivated (56°C, 1 h) serum. The virus-serum mixtures were
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incubated at 37°C for 1 h and assayed for residual infectious virus by 
inoculating duplicate FEK cell monolayers with 1 ml aliquots. Controls 
consisting of mixtures of virus dilutions with MEM were included for each 
test. For virus adsorption, inoculated cultures were incubated at 37°C 
for 1 h. Maintenance medium (5 ml) was added to each culture and 
incubation at 37°C was continued for 3 weeks when cultures were assayed 
for virus antigens according to previously described methods (1). The 
neutralization index for each serum was calculated as the difference in 
virus titre without serum and that of the virus-serum mixture. A
neutralization index of 1.7 was considered positive.
Monoclonal antibodies: The isolation and characterization of a panel of
monoclonal antibodies (MAbs) to glycoproteins of prototype EIAV has 
previously been described (11). These and other MAbs were used to
determine the antigenic changes in seven EIAV isolates. Two-month old 
BALB/c mice were immunized with purified EIAV isolate A/1 using
previously described protocols (11). Production of anti-virus antibodies 
was monitored in an indirect enzyme-linked immunosorbent assay (ELISA). 
Mice were sacrificed 3 days after the final boost and their spleen cells 
.fused with SP2/0 myeloma cells in the presence of PEG (50% PEG in
RPMI-1640 medium) (7). Hybridomas were screened for specific antibody 
production in ELISA (11) and Western blots and those secreting viral
glycoprotein specific antibodies were subcloned twice by limiting dilution. 
Ascites was obtained in pristane primed mice as previously described (11).
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Immunoblot analysis of EIAV isolates with equine sera and MAbs: EIAV
proteins were separated on 7.5 to 20% gradient gels in discontinuous 
buffer under reducing conditions (17) and blotted onto nitrocellulose 
membranes using previously described methods (2, 13). The nitrocellulose 
membranes were blocked for 2 h with 5% BLOTTO in TBS (lOmM Tris- 
HCL, 0.9% NaCl, pH 7.4) to prevent non-specific binding of antibody (14) 
and incubated with MAbs (1:20 dilution of ascites or 1:4 dilution of tissue 
culture fluid) or equine serum (at indicated dilutions) for 2 h. All 
incubations with antibody or with TBS containing 0.05% Tween 20 (SIGMA 
Chemicals, St. Louis, MO.) were done at 37°C with agitation. After a 20 
minute wash in TBS/Tween 20 the membranes were incubated for 1 h with 
horseradish peroxidase labeled second antibody. Affinity purified goat 
anti-mouse immunoglobulins (CAPPEL, COOPER BIOMEDICAL INC., 
MALVERN, PA) or rabbit anti-horse IgG (MILES-YEDA LTD, ISRAEL) 
were used at a dilution of 1:1000 or 1:3000, respectively. After two 
washes (final wash with TBS) bands specifically recognized by equine sera 
or monoclonal antibodies were developed with 4-chloro-l-naphthol in 
methanol (Bio-Rad, Richmond, CA).
Glycoprotein purification and peptide mapping: EIA V  glycoproteins
(gp90 and gp45) from isolates A/1-4 were purified on lentil-lectin affinity 
columns as previously described (21). Affinity purified glycoproteins were 
separated on discontinuous 10% SDS-PAGE (17). Gel slices containing 
gp90 and gp45 were radioiodinated and digested with trypsin. The 
released radioiodinated peptides were analyzed by two-dimensional thin 
layer chromatography and detected by autoradiography with Kodak X-
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Omat film (XRP-5) (5,6,22,31).
RESULTS 
Persistent infection in Shetland ponies.
First febrile episodes (defined as 39.5°C for 2 or more days) were 
observed between 16 and 19 DPI (Fig 1). Antibodies to EIAV antigens 
were detected in AGID on 25 DPI (A and B) and 29 DPI (C). After the 
first febrile episode the clinical course of the disease was variable. 
Ponies A and B had four and two febrile episodes, respectively, and pony 
C had only one febrile episode (Fig. 1). The duration of the febrile
episodes ranged from 2 to 4 days and each episode was characterized by
high fever, depression, inappetence and general weakness. All the 
episodes occurred within four months of infection. Ponies A and B died 
on 280 and 165 DPI, respectively, after several days of severe illness 
marked by depression, anorexia, loss of weight, prostration and diarrhoea. 
Pony C was euthanatized on 440 DPI after a similar severe illness.
Plasma samples collected during febrile episodes contained from 103-5
to 104-5 TCID50 of EIAV per ml (Fig 1). A total of seven isolates of
EIAV were recovered from plasma by end-point dilution in FEK cell 
cultures; virus isolates from sequential episodes from the same pony are 
numbered sequentially, e.g. A/1, A /2 etc. (Fig 1). The serologic 
characteristics of these viruses were analyzed in neutralization assays 
with convalescent sera, immunoblots with homologous and heterologous 
convalescent sera and MAbs. The structural alterations of EIAV 
glycoproteins were analyzed by tryptic peptide maps.
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Immunoblot analysis of equine sera during 
persistent infection with EIAV.
The protein binding specificities of sera collected during persistent 
infection with EIAV were analyzed in immunoblot assay. To obtain 
maximum transfer of gp90 and gp45, electroblotting from SDS-PAGE gels 
to nitrocellulose membranes was continued for 22 h at 75 V. With 
shorter transfer times, immunoreactivity with gp90 was less intense. 
Preinoculation sera were negative for EIAV specific antibodies (Fig. 2 
panel A). Serum collected after the first febrile episode from pony A at 
35 DPI had detectable activity to EIAV gp90, gp45 and p26 of isolates 
A/1, A /4 and prototype EIAV (Fig 2 panel B). The predominant activity 
was to the major envelope glycoprotein gp90 and the major core protein 
p26 at the 1:50 dilution used (Fig 2 panel B). The serum had similar 
activity with the other 5 isolates. Comparison of the seven isolates with 
prototype EIAV in SDS-PAGE showed minor variation in the rate of 
migration of the envelope glycoproteins with no variation in the migration 
of the core proteins (data not shown). Serum collected at 203 DPI 
contained high levels of antibody that bound extensively with gp90, gp45 
and p26 (Fig. 2 panel C). Several other bands were noted at the 1:100 
dilution used. As the level of IgG to these minor bands was generally 
low in infected horses, only those bands corresponding to gp90, gp45 and 
p26 were considered in the evaluation of humoral responses to EIAV 
isolates. Sera from naturally infected horses reacted with determinants 
of gp90, gp45 and p26 in the same viruses with levels of p26 activity 
lower than those to the envelope glycoproteins in most samples (Fig. 2
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panel D, and Fig. 3). Immunoblot analysis using serial dilutions of both 
35 DPI and 203 DPI sera indicated that the envelope glycoproteins are 
more highly immunogenic relative to their mass in the mature virion 
(Table 1).
Immunoblot analysis of EIAV isolates with MAbs to gp90 and
gp45.
The antigenic alterations in gp90 and gp45 during persistent infection 
were analyzed with MAbs. The activity of MAbs to gp90 (Fl-120 and Fl- 
123) and gp45 (Fl-106, Fl-102 and Fl-110) of isolate A /1 was tested 
against seven virus isolates including the prototype cell adapted EIAV 
(Table 2). The activity of these MAbs was analogous to that of MAbs 
previously shown to recognize epitopes 90-A and 45-A, respectively (11). 
As these MAbs appeared to be directed against highly conserved epitopes 
of EIAV they were grouped with those mapping to epitopes 90-A and 45- 
A, respectively. Analysis of viruses isolated from sequential and parallel 
febrile episodes with MAbs to prototype EIAV demonstrated the presence 
of variable and conserved epitopes in gp90 and gp45, respectively (Table 
3). The previously described classification of epitopes in gp90 (A-F) and 
gp45 (A-B) (11) was used in this study. Epitope 90-E was not detected in 
blots with all the seven virus isolates. The greatest antigenic variation 
was observed in the major envelope glycoprotein, gp90.
Appearance and specificity of EIAV neutralizing antibody.
Neutralizing activity was present in all three ponies by 67 DPI and 
was effective only for homologous virus isolates recovered prior to
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collection of the serum, i.e. 16 or 46 DPI (Table 4). Cross-neutralization 
with sequentially collected sera showed that isolates A /1-4 were 
serologically different. Serum collected from pony A later in the course 
of infection, i.e. at 203 DPI, had neutralizing activity for all virus
isolates recovered earlier in the infection (Table 4). Similar neutralizing 
activity was observed with sera collected from pony B. Serum collected 
from pony C late in the infection (438 DPI) neutralized several isolates of 
EIAV including the prototype virus (Table 5). The neutralization activity 
of 438 DPI serum was broad but could still distinguish serological
differences between the panel of virus isolates tested (Table 5). The 
specificity of neutralizing antibodies in late serum was broad and did not 
correlate with the number of sequential febrile episodes observed.
Analysis by peptide mapping.
The structures of the envelope glycoproteins of four virus isolates
recovered from sequential febrile episodes were analyzed by two- 
dimensional tryptic peptide mapping procedures. The peptide maps of the 
gp90 components of isolates A /l-A /4  (Fig. 4 row' A) indicate peptide 
additions and deletions when each virus isolate is compared with its most 
immediate progenitor. Thus, A /2 is compared to A/1, A /3 to A /2 and A/4 
to A/3, respectively. The results of each comparison revealed differences 
in the peptide maps of each pair examined. Between any two pairs 
examined, isolate A /4 had the greatest number of peptide additions.
Peptide maps were also obtained for the respective gp45 components of 
isolates A /l-A /4  (Fig 4 row B). Again pair-wise comparisons of the gp45 
peptide maps revealed the presence of additions and deletions.
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DISCUSSION
Our data on the antigenic variation of EIAV are in agreement with 
previous reports (11, 16, 22, 27, 28, 31). We further show in this report 
the kinetics of humoral responses to EIAV during experimental infections 
and extend our previous data on the antigenic and structural alterations 
occurring in the envelope glycoproteins during persistent infections.
In this study, the decline of viremia did not correlate with detection 
of antibodies capable of neutralizing EIAV in equine fibroblast cell 
cultures. Neutralizing activity was detectable within two months and was 
effective against only those viruses recovered during prior febrile 
episodes suggesting that the neutralizing antibodies were type specific. 
The occurrence of recurrent febrile episodes and the specificity of 
neutralizing antibodies observed during chronic EIA suggest that 
conserved antigenic determinants detectable in the envelope glycoproteins 
do not elicit sufficient protective immune responses. The specificity of 
neutralizing antibody observed in vitro broadened during the course of 
EIA suggesting that multiple stimulation of the immune system with one 
or more EIAV strains was necessary to generate this activity. These data 
are in agreement with those of Kono et al. (15) who showed that 
neutralizing antibody as assayed in horse leukocyte cultures appeared 
from 45 to 87 DPI and reached peak titers from 90 to 148 days. The 
rapid appearance of high levels of neutralizing antibodies to the isolates 
recovered after 45 DPI is suggestive of either immunological priming with 
heterologous isolates or the presence of sensitizing levels of homologous 
isolates preceding each recurrent febrile episode. These studies showed 
that the neutralizing activity persisted for a long time. Although all
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three ponies died within one and half years after infection despite the 
presence of potent neutralizing antibodies, several ponies infected with 
the plasma used in this study have lived for over 8 years suggesting that 
early death may have been due to other causes.
The envelope glycoproteins of prototype EIAV and the seven isolates 
in this study contain highly antigenic group-specific determinants which 
in immunoblot assays reacted strongly and more consistently than those 
associated with the major core protein, p26. This and other studies (13) 
have shown that in many naturally infected horses, antibodies to the viral 
core proteins are often undetectable in Western blots when serum is 
diluted 1:50. In contrast, activity with the envelope glycoproteins was 
uniformly detected in sera with positive AGID results. No correlation was 
detected between the length of infection and the levels of antibodies to 
the core proteins. The lower levels of antibodies to p26 could result 
from abundant production of core proteins that may remove specific 
antibody from circulation.
We have previously demonstrated that virus isolates recovered from 
ponies inoculated with the virus strain used in this study could be 
distinguished with panels of MAbs to gp90 and gp45 of EIAV (11). Both 
conserved and variable epitopes have been identified in gp90 and gp45, 
respectively (11). Analysis of seven isolates with the same panel of MAbs 
demonstrated antigenic variability in gp90 and gp45. Most of the epitopes 
in gp90 were variable and appeared to evolve randomly. The antigenic 
variation occurred both before and after the appearance of detectable 
neutralizing antibodies suggesting that selection processes other than by 
neutralizing antibodies are involved in EIA. Similar observations have
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been made in other studies which demonstrated nucleotide, 
oligonucleotide, peptide and glycopeptide variation in isolates recovered
from febrile episodes that occurred 2-3 weeks after infection (22, 27, 28,
31). The random appearance and disappearance of epitopes in the major
envelope glycoprotein and the pattern of neutralization observed with 
convalescent sera suggest that the neutralization antigenic sites are
altered during persistent infection.
Tryptic peptide mapping of gp90 and gp45 components of four virus
isolates (A /l-A /4) recovered from sequential episodes separated by as 
little as 4 weeks showed several peptide map additions and deletions
occurring between each isolate and its predecessor. Our data are in 
agreement with results of previous analyses of EIAV isolates and further 
indicate that each febrile episode is caused by a distinct virus population 
(22, 31). Cross-neutralization assays, Western blotting with MAbs and 
peptide mapping of EIAV isolates indicate that each procedure may 
classify the variants into different groups. The maps generated for these 
virus isolates were different from those previously reported for parallel
isolates (22, 31). Previous studies have shown alterations in the peptide,
glycopeptide and oligonucleotide maps of isolates recovered during
sequential febrile episodes (26, 28, 31). More recently we have shown 
that isolates with altered immunoreactivity patterns, peptide, glycopeptide
or oligonucleotide maps have numerous clustered base substitutions in the 
region coding for the outer envelope glycoprotein indicating that the 
observed antigenic and structural variations have a genetic basis (28).
Antigenic variation in this virus can therefore be explained by the
appearance of random point mutations in the envelope gene. Mutations
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affecting amino acid residues that either form neutralization antigenic
sites or which are crucial in the tertiary folding of the envelope 
glycoproteins can alter the antigenicity of the protein and render it 
unreactive with existing protective immune factors. Moreover, alteration 
of glycosylation patterns may alter the antigenicity of the viral 
glycoproteins allowing progeny virus to infect cells in the presence of 
immune factors specific for parental virus. The observation that 
cessation of recurrent febrile episodes was associated with presence of 
neutralizing antibodies with broad specificity suggests that multiple
stimulations of the immune system with several strains of EIAV may
generate the necessary immune factors important in the control of virus 
replication. Although the nature of these immune factors that eventually
control the cycles of virus replication have not yet been identified, 
results lead us to suggest that immunogens derived from several strains 
or serotypes of EIAV may be needed to confer protection.
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Fig. 1: Clinical histories of Shetland ponies experimentally infected with
EIAV. All sustained rectal temperature recordings 39.5°C 
(dashed line) were considered febrile episodes. The infectivity
titers in FEK cells of plasma obtained during the febrile periods 
are shown as log10 TCID50/m l (vertical bars). Virus isolates 
recovered from the respective febrile episodes are shown, e.g. 
A/1 to A/4, etc. (A) pony F135, (B) pony P135 and (C) pony 
P130.
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Fig. 2: Western blot reactivity patterns of convalescent sera during
persistent infections. Representative data for the patterns of 
protein specificity of serum antibody are presented. Pre­
inoculation serum at 1:50 dilution against isolate A/1 (panel A). 
Serum from pony A on 35 DPI (1:50) (panel B) and 203 DPI 
(1:100) (panel C), respectively and EIA reference serum (1:100) 
(panel D). Viruses A/1, A /4 and prototype EIAV are in lanes 1, 
2 and 3 of panels B-D, respectively.
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Western blot reactivity patterns of sera from naturally infected 
horses. The protein specificities of four serum samples were 
tested at 1:50 dilution. Normal horse serum is tested against 
prototype EIAV in lane 0. Sera from four naturally infected 
horses are tested in lanes 1-4 against prototype EIAV (panel A) 
and isolates A/1 (panel B) and A /4 (panel C), respectively.
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Fig. 4. Tryptic peptide maps of 125I-gp90 (row A) and 125I-gp45 (row B) 
isolated from EIAV strains A/1, A/2, A /3 and A/4. Peptide 
additions (Arrows) and deletions (circles) indicate peptide map 
differences for each isolate when compared with that of 
immediate predecessor, i.e. A /2 is compared with A/1, A /3 with 
A /2 etc.
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Table 1: IgG levels to EIAV glycoproteins and major core protein present 
in early (35 DPI) and late (203 DPI) sera by Western blot.
Viral
protein
Percentage 
in virion*
LEVELS 
Early serum
OF IgG
Late serum
gp90 6.0 3.3a 4.2
gp45 3.0 2.0 3.7
p26 45.0 3.3 4.2
adapted from Parekh et al (25). 
a Log10 of the reciprocal of highest serum dilution positive for specific 
IgG binding.
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Table 2: The protein specificities of MAbs to isolate A /1 and their 
reactivity with EIAV isolates in Western blots.
VIRAL VIRUS ISOLATES
MAba PROTEIN A/1 A/2 A/3 A/4 B /l B/2 C/1 Pb
Fl-120 gp90 + + + + + + + +
F I-123 gp90 + + + + + + + +
Fl-102 gp45 + + + + + + + +
Fl-106 gp45 + + + + + + + +
Fl-110 gp45 + + + + + + + +
a supernatants from hybridoma cell cultures were used at 1:4 dilutions. 
b prototype cell adapted strain of EIAV.
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Table 3: Immunoblot patterns of gp90- and gp45-specific MAbs with 
polypeptides of seven EIAV isolates including prototype EIAV
(P).
VIRUS ISOLATES
EPITOPES3 P A/1 A/2 A/3 A/4 B /l  B/2 C/1
90-A + + + + + + + +
90-B + - + + - + + +
90-C + + + + - + - +
90-D + + + + - + - +
90-E +
90-F + - + + - + - +
45-A + + + + + + + +
45-B + - + + + + + +
a - epitopes in gp90 and gp45 (11)
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Table 4. Neutralization of EIAV isolates by sera collected from pony A 
on different days post-inoculation (DPI).
SERUM COLLECTION DAY
EIAV- ISOLATE 35* 67 90 203 279
A/1 (16a) 1.5b 3.5 3.5 3.0 3.5
A /2 (46a) 1.5 3.0 3.0 2.0 2.0
A/3 (75a) 1.5 1.5 2.5 2.5 2.0
A/4 (107a) 1.0 1.0 1.5 2.5 2.5
DPI serum collected 
a DPI virus isolated 
b Logio neutralization index (1.7 positive)
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Table 5. Neutralization of EIAV isolates by serum collected from pony C 
that had only one clinical episode of EIA.
SERUM COLLECTION DAY
EIAV PASSAGE VIRUS ISOLATE 35a 438
PO* Prototype 1.5 3.0
P2 P2-1 1.0 3.5
P2-6 1.0 3.5
P3 A/1 1.5b 3.0
A /2 1.5 2.0
A/3 1.5 2.0
A/4 1.0 1.5
B /l 1.5 2.5
B/2 1.5 2.0
C/1 1.0 3.5
EIAV passage in Shetland ponies 
a DPI serum collected 
b Log10 neutralization index (1.7 positive)
CHAPTER THREE
IN VITRO ISOLATION OF A NEUTRALIZATION ESCAPE MUTANT OF 
EQUINE INFECTIOUS ANEMIA VIRUS (EIAV).
SUMMARY
An equine infectious anemia virus isolate (A/1) from the plasma of 
a pony with clinical signs of equine infectious anemia was serially 
propagated in fetal equine kidney cell cultures in the presence of 
neutralizing convalescent serum. After 13 passages, an escape mutant 
(A /IE ) was isolated which resisted neutralization by the homologous 
serum. Resistance to neutralization of A /IE  was associated with loss of 
epitope(s) in the major envelope glycoprotein, gp90. Our data confirmed 
that antigenic variation is an important mechanism for the persistence of 
this virus in the presence of neutralizing serum.
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INTRODUCTION
Lentiviruses of man and animals cause persistent infections in their 
respective hosts. The equine lentivirus, equine infectious anemia virus 
(EIAV), causes a persistent infection often characterized by recurrent 
episodes of acute illness marked by high fever (2). Besides persisting in 
their hosts as integrated proviruses, lentiviruses may persist in
immunologically responsive hosts by undergoing antigenic variation. The 
occurrence of genomic and antigenic variation in EIAV during persistent 
infections in horses has been documented using a variety of serological 
and biochemical assays (3, 6, 8, 9, 10, 11). Analysis of virus isolates 
recovered from sequential febrile episodes with a panel of monoclonal 
antibodies (MAbs) has documented the presence of common and variable 
epitopes in the major envelope glycoprotein of EIAV, gp90 (3).
Nucleotide sequence data has revealed a high mutation rate of this 
lentivirus genome during persistent infections (10). It is generally 
thought that neutralizing antibodies aid in the selection of new antigenic 
virus variants during persistent infections. In infections with EIAV, 
serologically distinct variants emerge possibly through immune selection 
pressure operating on random viral genome mutations. To assess the 
possible role of neutralizing antibody in the emergence of new virus vari­
ants, we generated a neutralization escape mutant of EIAV and 
demonstrated that resistance to neutralization by immune serum was
associated with loss of at least one epitope in the major envelope 
glycoprotein, gp90.
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To generate a neutralization escape mutant, a third passage isolate of 
EIAV (A/1) was recovered by end-point dilution of plasma from pony A 
during the first febrile episode in fetal equine kidney (FEK) cells (11). 
This isolate was serially propagated in FEK cells in the presence of 
homologous serum. As a plaque assay does not exist for this virus, the 
end-point dilution method was used to recover the predominant virus
population present in the plasma. The virus (A/1) and the homologous 
serum used in this study were collected from pony A on 16 and 203 days 
post-inoculation (DPI) respectively (11). The homologous serum had a 
neutralization index of 3.5 against isolate A/1. The conditions for the
propagation of FEK cells have previously been described (7). In this 
study, the FEK cells (grown in 25 cm2 tissue culture flasks) were 
inoculated with A/1 at a multiplicity of infection of 0.01 and incubated at 
37°C for 1 h. After virus adsorption, cell cultures were rinsed with 
warm phosphate buffered saline (PBS, pH 7.2) and 5 ml of maintenance 
medium (MEM + 3% fetal calf serum) were added. After 72 h, heat 
inactivated (56°C, 1 h) homologous serum was added (final concentration, 
10%) and incubation at 37°C was continued for 3 weeks. Clarified super­
natant medium obtained after 3 weeks was used as inoculum for the serial 
passage of A /1 in FEK cell cultures in the presence of homologous serum. 
During the subsequent passages, virus-serum mixtures were inoculated 
onto FEK cell monolayers and maintenance medium containing immune
serum was added after virus adsorption without any rinsing. Thus, in a 
manner analogous to the conditions that exist in persistently infected
horses, the homologous serum was maintained in the cultures at all times 
during the subsequent passages of A/1. The A/1 isolate of EIAV was
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propagated in the presence of homologous serum for a total of 13 pas­
sages. The ability of the homologous serum to neutralize A/1 at different 
levels of passage was tested in the alpha method of virus neutralization. 
During the final passage in the selecting serum, the virus was pre­
incubated with an equal volume of undiluted serum and inoculated onto
- FEK cells. The recovered virus was "cloned" by end-point dilution in
FEK cell cultures and designated as A /IE  to denote a neutralization esc­
ape mutant derived from isolate A/1. The serological relatedness between 
A/1 and A /IE  was assessed by virus neutralization using homologous and 
heterologous sera. The heterologous serum was collected on 438 DPI from 
pony C which had received the same inoculum as pony A (11). The
details for virus neutralization are described elsewhere (11). Briefly, 
serial 10-fold dilutions of each virus were mixed with a standard dilution 
(1:4 in MEM) of heat inactivated (56°C, 1 h) serum. The virus-serum 
mixtures were incubated at 37°C for 1 h and assayed for residual
infectious virus by inoculating duplicate FEK cell monolayers with 1 ml
aliquots. Controls consisting of mixtures of virus dilutions with MEM
were included for each test. Virus antigens were assayed as previously
described (1). The neutralization index for each serum was calculated as 
the difference in virus titre between samples without serum and that of 
the virus-serum mixture. A logi0 neutralization index (LNI) of 1.7 was 
considered positive.
The ability of virus isolate A/1 to resist neutralization by the 
homologous serum was monitored by virus neutralization assay. The LNI 
of virus A/1 after six serial passages (A /1/6) in the presence of
homologous serum was 1.5 lower than that observed for the parent virus
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(Table 1). A difference of 1.5 LNI was observed in virus isolates 
recovered from sequential febrile episodes (11) implying that after six 
serial passages A/1 in the presence of neutralizing antibodies a significant 
antigenic alteration had occurred. The virus was further propagated until 
by 13 passages it completely resisted neutralization by homologous serum 
and had a modified neutralization pattern by heterologous serum (Table 
1). These data indicated that after multiple passages of EIAV in the 
presence of immune serum the virus had altered antigenic sites which led 
to inability of homologous serum to neutralize. Partial recognition of the 
acquired neutralization antigenic sites by heterologous serum suggested 
either that the specificity of the selecting serum may determine the 
serological divergence of the new virus strain or that more than one site 
is involved in virus neutralization. The. failure of the selecting serum to 
neutralize the new virus variant (A / IE) is analogous to what happens in 
chronic ELA when virus variants emerge in the presence of antibodies 
with type-specific neutralizing activity and antibodies reacting with 
group-specific determinants of the envelope glycoproteins (11). New virus 
populations could emerge during persistent infections in horses as a result 
of high replicase errors associated with the reverse transcription of virus 
genome and immune selection pressure. Our data documented for the 
first time that antibody-mediated immune selection pressure can operate 
in the emergence of new serological variants of EIAV. The process was 
gradual and required multiple passages in the selecting serum. During 
chronic EIA, virus isolates are serologically different even when recovered 
during sequential disease episodes separated by as little as four weeks 
(11). The rapid evolution of EIAV during persistent infection in horses
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may be due to the lytic infection of highly permissive cells (i.e., monocy­
tes and macrophages) a process that would lead to multiple cycles of 
virus replication amplifying the replicase errors associated with reverse 
transcription. Immune selection pressure then operates on a markedly 
heterogeneous virus population allowing virus variants to emerge rapidly. 
In contrast, the replication of EIAV in cultured equine fibroblasts is non- 
lytic and less permissive. During persistent infection in these cells, 
resistance to homologous superinfection may be mediated by viral receptor 
down-regulation as a result of the complexing of receptor with viral 
envelope proteins. This could limit the cycles of virus replication 
involving reverse transcription. Such a process would limit the rate of 
viral genome change occurring in persistently infected cells. Antibody 
selection pressure is then likely to operate on less heterogeneous virus 
populations and new virus variants would take longer to appear in vitro 
than in vivo.
The emergence of a serological variant of EIAV after several passages 
of an end-point diluted virus in the presence of neutralizing serum su­
ggested that the variants recovered during chronic EIA are not all 
present in the inoculum virus. Our data indicated and confirmed that 
antigenic variation in the equine lentivirus is one of the mechanisms by 
which this virus can persist in the presence of immune serum. The 
alteration of neutralization antigenic sites of EIAV in this variant did not 
involve the functionally conserved domain which allows replication in 
equine fibroblasts. This suggested that at least this functionally 
conserved domain of EIAV is not the target for neutralization of virus 
infectivity. Moreover, immunoblot analysis of A/1 and A /IE  with the
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selecting serum (Fig 1) were similar further indicating that antibodies 
recognizing conserved antigenic domains in gp90 and gp45 are not 
involved in virus neutralization.
To further characterize the neutralization escape mutant, A /IE  was 
propagated in FEK cell cultures and purified using previously described 
methods (5). The viral proteins were separated under reducing conditions 
on 7.5 to 20% gradient gels by SDS-polyacrlyamide gel electrophoresis and 
transferred to nitrocellulose membranes as described elsewhere (11). All 
incubations with antibody or with Tris-buffered saline (lOmM Tris-HCl,
0.9% NaCl, pH 7.4) (TBS) were at 37°C with agitation. The nitrocellulose 
strips were blocked for non-specific binding of antibody with 5% non-fat 
dry milk (4) in TBS for 2 h and incubated for 2 h at 37°C with monoclo­
nal antibodies (MAbs) at 1:20 dilution or equine serum (203 DPI serum) at 
1:100 dilution in TBS containing 1% non-fat dry milk- After incubation
with MAbs or serum, the strips were washed twice (10 min/wash) in TBS
containing 0.05% Tween 20 (SIGMA) and incubated for 1 h with peroxidase 
labeled goat anti-mouse immunoglobulins (CAPPEL, COOPER BIOMEDICAL, 
INC., MALVERN, PA) rabbit anti-equine IgG (SIGMA Chemicals, St Louis, 
MO.) diluted at 1:1000 in TBS containing 1% non-fat dry milk,
respectively. The strips were processed for color with 4-chloro-l-
naphthol in methanol (Bio-Rad, Richmond, CA).
The production and characterization of MAbs 86, 82, and 115 has 
previously been described (3). MAb 86 recognizes an epitope (90-A) that 
exists in all the EIAV isolates tested (3) including A/1 and A /IE , 
respectively (Fig 2). Our results indicated that during serial propagation 
of A/1 in homologous serum, the epitopes recognized by MAbs 82 and 115
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were apparently altered and could not be detected in A /IE  by Western 
blot. Although MAbs 82 and 115 failed to neutralize A/1, our data 
demonstrated that resistance to neutralization by equine convalescent 
serum was associated with loss of epitopes recognized by these MAbs. 
All three MAbs used in this study reacted with the gp90 of a virus 
isolate A /2 the in vivo homologue of isolate A /IE ) that was recovered 
from pony A four weeks after the isolation of A/1 (11), indicating that 
new virus variants emerged from the predominant virus population in a 
random fashion. The consideration that A /IE  is the homologue of A /2 
assumes that, in vivo, virus variants evolve from the predominant virus 
population i.e. A/1. Previous data has shown that gp90 is a target for 
neutralizing MAbs and during persistent infections rearrangement of epit­
opes occur in gp90 with minor or no alterations in gp45 (11). Moreover, 
analyses of sequential and parallel isolates of EIAV recovered from ponies 
infected with the same virus have shown that the isolates are structurally 
and genetically different (9, 10, 12 ). In contrast, antigenic and
structural alterations in gp90 and gp45 have not been observed during 
continued propagation of EIAV in cell cultures in the absence of immune 
serum (6). The appearance of structurally and antigenically distinct 
variants of EIAV before the development of neutralizing antibodies, 
however, indicates that selection of virus variants also involves 
mechanisms other than by neutralizing antibodies (11).
Our data confirmed previous observations that EIAV is a highly 
mutable virus. During persistent infection in horses, antibody selection 
pressure could result in the emergence of novel variants that cause the 
recurrent febrile episodes associated with chronic EIA in a manner
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analogous to our in vitro model. The generation of a virus variant from 
end-point diluted virus indicates that the viruses that are recovered from 
persistently infected horses may evolve from a single virus population by 
random mutations in the viral envelope gene. Selection of this mutant 
was enhanced by immune selection pressure. Further characterization of 
this in vitro isolate will be necessary. Preliminary data indicate that the 
in vitro isolate maintained its virulence and infectivity for ponies as signs 
of clinical EIA were observed within 10 days of inoculation (Issel, 
unpublished results). Nucleotide sequence analysis of A /IE  and A/1 
isolates may help identify sequences that are important in antibody- 
mediated immune selection pressure either alone or with other immune 
factors present in infected animals, respectively. Moreover, the 
generation of virus variants in vitro using either defined sera or 
monoclonal antibodies and their subsequent genetic analyses will help to 
identify sequences that frequently change during virus replication. 
Identification of such sequences may be important in the design of 
effective immunogens for EIA. The antigenic variation documented for 
EIAV during persistent infection in horses and in cell culture in the 
presence of neutralizing antibodies may be a general mechanism for the 
persistence of lentiviruses of man and animals in immunoresponsive hosts.
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Fig 1: Western blot analysis of the neutralization escape mutant A /IE
and the parent virus A/1 with the selecting immune serum. 
Reference EIA negative equine serum is tested in lane 1 against 
isolate A /IE  at 1:50 dilution. Isolates A /IE  and A/1 are tested 
in lanes 2 and 3, respectively with 203 DPI serum at 1: 50 
dilution.
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Fig. 2: Western blot analysis of EIAV isolates A/1 (parent) and A /IE
(neutralization escape mutant) with a panel of MAbs reactive 
with the major envelope glycoprotein, gp90. MAbs 86 (lane a), 
82 (lane b) and 115 (lane c) were used at 1:10, respectively. 
Virus A/1 (panel A) and neutralization escape mutant A /IE  
(panel B).
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Table 1. Neutralization of EIAV isolates A/1 and A /IE  by homologous and 
heterologous equine convalescent sera.
VIRUS
SERUM A/1 A/1/6* A/1E+
Homologous 3.5+ + 2.0 0.7
Heterologous 3.0 ND 2.0
A/1 virus after 6 passages in the presence of homologous serum.
+ A /IE  isolated after 13 passages of A/1 in the presence of homologous 
serum.
+ + Log10 neutralization index ( 1.7 positive).
ND - not done.
CHAPTER FOUR
APPLICATION OF THE SINGLE-STEP IMMUNOBLOT (SIB) TEST IN 
DIAGNOSIS OF EQUINE INFECTIOUS ANEMIA AND DETECTION OF
ANTIGENS OF EIAV.
SUMMARY
A simple and rapid single-step immunoblot (SIB) assay for antibodies 
to specific antigens of equine infectious anemia virus (EIAV) was 
compared with AGID, competition-ELISA and Western blot. A high 
correlation was observed between these serologic tests in samples with 
weak positive or positive AGID reactions. Samples with equivocal AGID 
reactions (8%) tested positive for anti-EIAV antibodies in C-ELISA and 
Western blots, respectively. These samples could be positively identified 
with the SIB test using a combination of viral gp90 and p26. In the SIB 
test, sera were incubated with viral antigens in the presence of "SIB 
reagent", a protein A-colloidal gold suspension containing a blocker for
non-specific binding of antibody. Results to detect equine IgG in Western 
blots were comparable using peroxidase labeled rabbit anti-equine IgG or 
SIB reagent. The advantages of SIB include speed, low cost and lack of 
background problems often seen in Western blots when low serum
dilutions are used. The SIB test was found to be applicable for rapid
detection of EIAV p26 antigen in fluids from infected cell cultures. The
test has potential for wide application in diagnosis of human and animal 
viral infections.
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INTRODUCTION
Equine infectious anemia virus (EIAV) causes a persistent infection in 
horses that is often characterized by recurrent febrile episodes (3, 5). 
Horses infected with EIAV produce antibodies to most if not all the viral 
proteins. Antibodies to EIAV antigens can be detected in the serum of 
infected horses in a number of serological assays including the agar gel 
immunodiffusion (AGID) test (4), enzyme linked immunosorbent assay (14) 
and Western blotting (6). As horses infected with EIAV remain viremic 
for life and pose a threat to uninfected horses, their rapid and accurate 
identification is imperative in the control of this disease.
Although AGID test seropositivity correlates very highly with
infection, the test lacks the sensitivity to identify all infected
seropositive horses (6). In such cases, other testing procedures including 
competition-ELISA (C-ELISA) and Western immunoblot have proven more 
sensitive than the AGID test (6). The rapid and accurate diagnosis of 
virus infections is an important facet in disease control programs. A 
need exists for continued search of diagnostic procedures that are 
sensitive, specific, rapid and easy to use. In this study, the use of a 
rapid, accurate and easy to perform single-step immunoblot (SIB)
procedure for the detection of EIAV antibodies was evaluated. The assay 
is based on the binding of specific serum antibodies to solid-phase 
adsorbed viral antigens and detection by a protein A gold probe. The
test has enormous applicability as antibodies to many antigens/infectious 
agents can be simultaneously detected.
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MATERIALS AND METHODS
Virus antigens: The cell culture adapted Wyoming strain of EIAV
(prototype virus) (10) was produced in fetal equine kidney cell cultures 
and purified using previously described procedures (11). The EIAV major 
envelope glycoprotein gp90 and the major core protein p26 were purified 
from density gradient purified virus in a reverse-phase high performance 
liquid chromatography (HPLC) column as described elsewhere (8). 
Recombinant p26 covering the Pvu/Dra site in the gag gene was cloned 
and expressed in E. coh as a fusion protein containing half of pl5, entire 
p26, 8 residues of p l l  and 38 amino acids of trp L (Payne, unpublished 
results). The recombinant antigen was solubilized in 8M urea. The AGID 
test kits were commercially obtained from Pittman-Moore, Washington 
Crossing, NJ and C-ELISA test kits were kindly supplied by Tech America 
Corp. Kansas City, MO.
Serum samples: The routine diagnosis of EIA is based on the detection
of anti-virus antibodies in AGID or C-ELISA test. Equine sera were 
collected from a variety of geographical areas in the United States and 
tested for anti-virus antibody in the AGID test. A total of 115 sera 
were tested in C-ELISA, Western blots and the SIB test. Five of these 
sera were from horses previously known to be AGID test positive and 
which subsequently became equivocal or negative AGID reactors. 
International reference serum (IRS) for EIA was obtained through Dr. Jim 
Pearson (USDA Veterinary Services Laboratory, Ames Iowa) and was used 
in all the four serologic tests for comparison. EIA positive serum (Lady)
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with a strong AGID reaction, sera with weak AGID reactions and pooled 
EIA negative serum were included as controls. Rabbit anti-p26 serum was 
prepared by immunizing rabbits with HPLC purified EIAV p26.
AGID test and C-ELISA: The AGID test was conducted using the approved
protocols (12) and was read after 24 h according to manufucturer’s 
criteria. Samples which caused a deviation of the reference positive 
serum precipitation line similar to that observed with IRS, but did not 
form a line in common with reference positive serum, were judged as 
weak positive reactions. Samples which led to a disagreement in the 
interpretation of the reaction by three trained individuals were regarded 
as equivocal. Those samples which formed a line of precipitation in 
common with the reference line were interpreted as positive. The C- 
ELISA test was performed according to the manufacturer’s procedures
(TechAmerica Corp., Kansas City, MO). Samples which visually gave an 
equal or lower intensity of color than the reference positive sample were 
considered positive.
Protein A-gold conjugation: Colloidal gold particles of uniform size (15
or 30 nm) were produced by reduction of 0.01% tetrachlorouric acid with 
1% sodium citrate according to previously described methods (15). The pH 
of the colloidal gold sol was adjusted to approximately 7.0 with 0.01M 
K2C 0 3 and the optimum amount of Staphylococcus aureus protein A
(SIGMA Chemicals, St. Louis, MO) in 0.05M Tris buffer (pH 7.4) added.
After testing the stability of protein A-gold with 10% NaCl (a blue 
precipitate forms upon addition of NaCl when the amount of protein
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present is insufficient to protect the colloidal gold from salt-induced 
flocculation), Tris buffer containing 0.1% polyethylene glycol 20M (PEG 
20M) was added. The protein A gold solution in 0.05M Tris buffer (pH
7.4) containing 2.5-4% non-fat dry milk (Carnation) as a blocker was used 
as the detecting reagent. The detecting reagent (subsequently referred to 
as the SIB reagent) could be stored at 4°C for up to 1 year.
Determination of optimum amount of antigen and serum dilution for 
single-step immunoblot (SIB): Density gradient purified virus was
treated with 4M KSCN (v/v 1:10) for 15 minutes at 37°C. The disrupted 
virus, p26, recombinant p26 and gp90 were diluted in Tris-HCl (0.05M, pH
7.4) to include a concentration range of 200ng/il to 1.5ng/il. The 
antigen dilutions were spotted in ill aliquots on a support matrix 
(nitrocellulose membrane, 0.45um, Schleicher and Schuell, Keene, NH), 
incubated at 56°C for 20 minutes to dry and fix antigen, and placed into 
test-tubes containing the SIB reagent. Each panel of antigen dilutions 
was tested against sera with negative, strong or weak AGID reactions for 
virus specific antibodies, respectively, at three final dilutions: 1:10, 1:100 
and 1:1000. The appropriate volume of each serum was added directly to 
the SIB reagent containing the specific antigen(s). The antigen 
preparations were also incubated with the SIB reagent but without serum 
as control for non-specific binding of colloidal gold. The tests were 
incubated at room temperature with agitation. The development of a 
colored spot at the site of antigen indicated the presence of specific 
antibody. As rabbit IgG binds with protein A with high affinity and the 
SIB reactions occur faster, rabbit anti-p26 serum was used for assessing
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activity of the SIB reagent.
SIB test for EIAV antibody: For detection of antibodies to EIAV in the
sera of test horses, HPLC-p26 (40ng/il) in Tris-HCl buffer (0.05M, pH 7.4) 
was spotted on the support matrix as described above and incubated in 
the SIB reagent containing a 1:100 final dilution of test serum. Sera with 
weak or equivocal AGID or C-ELISA reactions were tested in SIB using a 
panel of viral p26, recombinant p26 and gp90 blotted on the same strip of 
nitrocellulose membrane.
Western blot: EIAV proteins were separated on discontinuous (4%
stacking gel), 7.5 to 20% gradient gels by SDS-PAGE under reducing 
conditions (9). The separated viral proteins were electroblotted to 
nitrocellulose membranes (0.45im, Schleicher and Schuell) according to 
previously described methods (2). Nitrocellulose membranes containing 
separated EIAV proteins were incubated with 5% non-fat dry milk (7) in 
Tris buffered saline (TBS) (lOmM Tris, 0.9% NaCl, pH 7.4) for 2 h at 
37°C. Serum samples (n=78) were tested against prototype EIAV and two 
antigenically different strains of EIAV (isolates A/1 and A/4) isolated 
from a pony during recurrent febrile episodes. All serum samples were 
diluted in TBS containing 1% non-fat diy milk and incubations and washes 
were done at 37°C with agitation. The membranes were then incubated 2 
h with test sera (1:50), washed twice (10 min/wash) in TBS containing
0.05% Tween 20 (SIGMA) and incubated for 1 h with peroxidase labeled 
rabbit-anti horse IgG (1:3000; MILES-YEDA LTD, ISRAEL). After two 
washes (10 min in TBS/0.05% Tween-20 and 10 min in TBS) bound
104
antibody was detected with 4-chloro-l-naphthol (Bio-Rad, Richmond, CA) 
in TBS. Specific viral antibodies were also detected in the SIB test in 
which case the nitrocellulose membranes containing separated EIAV 
proteins were incubated for 2-4 h in SIB reagent containing 5% (w/v)
non-fat dry milk and 1:100 of the test serum.
Detection of EIAV antigen in the SIB test: Supernatant media from
infected and uninfected cell cultures were treated with 40% polyethylene 
glycol (PEG) and assayed for EIAV antigen essentially as previously
described (1). For detection of EIAV antigens in the SIB test,
supernatant media from known infected and uninfected cell cultures were 
clarified at 1,000 x g, treated with 40% PEG for 1 h and precipitated by 
centrifugation at 1,500 x g for 1 h. The precipitated materials were
resuspended in 50il of borate buffer (0.05M, pH 8.6), 8M urea, 5% SDS or 
4M KSCN. An equal volume of di-ethyl ether was added to the borate 
buffer mixture. For disruption of virus, the mixtures were incubated with 
these reagents at 37°C for 15 minutes. Aliquots of each sample (lil) 
were then spotted on nitrocellulose membrane and incubated at 56°C for 
20 minutes for protein binding. The membranes containing test antigens 
and 40ng of p26 (positive antigen control) were incubated in SIB reagent 
containing 1:100 of rabbit anti-p26 serum.
105
RESULTS 
Optimum conditions for SIB test.
The optimum concentration for each antigen preparation was 
determined in a checker-board titration of antigen and EIA positive or 
negative sera. An antigen concentration which gave positive reactions 
against sera with weak AGID reactions and negative reactions with 
reference EIA negative serum was selected as optimum for the test. 
Detergent disrupted EIAV showed low specificity for anti-virus antibody 
as some sera negative in AGID and Western blot tested positive. The 
concentrations of HPLC-p26 and recombinant p26 that gave high 
specificity and strong intensity of color reactions were 40ng and 200ng, 
respectively (Table 1). For sera that tested strongly in AGID, as little as 
3ng of viral p26 and 12ng of recombinant p26, respectively, could be used 
(Table 1). Purified gp90 was used at 50ng for sera with positive AGID 
reactions and lOOng for sera with weak positive AGID reactions. The 
kinetics of the SIB test were different for equine and rabbit sera and 
were influenced by the serum dilution and the relative amounts of EIAV 
specific antibodies in each serum (Table 2). The influence of species and 
serum dilution on the kinetics of the reaction was greatest for the equine 
serum probably as a result of the low affinity of protein A for equine 
IgG compared with that of rabbit. From the kinetics data, an optimum 
serum dilution of 1:100 was selected for equine sera. For rabbit serum, 
dilutions greater than 1:100 could be used effectively. With these 
standards, the SIB test using protein A-colloidal gold conjugate was used 
to detect antibodies to EIAV in equine serum with results evident within
4 h in all but sera with weakest positive AGID reactions.
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Detection of anti-EIAV antibodies in AGID, C-ELISA and 
Western blot.
All serum samples were initially tested by AGID and C-ELISA. The 
samples were grouped as negative, equivocal, weak positive or positive 
according to their AGID results (Table 3). All the samples with equivocal 
AGID reactions gave positive reactions in C-ELISA and had reactivity to 
EIAV gp90 in Western blots (Fig. lanes 3, 4, 5, 7, 8 and 9). Five of the 
six samples also had reactivity to EIAV gp45 and p26. It was necessary 
to dilute serum samples fifty fold to eliminate background staining in 
Western blot. Two samples (10165 and 10126) from a horse (mare 4) with 
a history of AGID test positive results were AGID test negative but 
positive in Western blot at the time of this study (Fig 1, lanes 3 & 9). 
Sample 10165 was also positive in C-ELISA and had comparable activity to 
that of IRS in Western blot (Fig. 1, lanes 2 & 3). All samples with 
equivocal AGID reactions and 2 samples with negative AGID reactions had 
high activity to gp90 in Western blot.
There was complete agreement in AGID, C-ELISA and Western blot 
results for groups of samples with weak AGID results (Table 1). All 63 
samples had detectable reactions against gp90, gp45 and p26 of prototype 
EIAV, isolate A/1 and isolate A/4, respectively. Strong activity to gp90 
and gp45 and weak activity to p26 was observed at the 1:50 serum 
dilution used. Differential reactivity to gp45 of the three virus strains
was observed with a few of the serum samples with positive AGID results 
(Fig. 1, lanes 10-12).
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The reactivity of equine sera with EIAV proteins separated on SDS- 
PAGE and blotted to nitrocellulose membranes was also detected in the 
SIB test. With EIA positive sera, intense color developed within 2-4 h 
(Fig. 2). Western blots developed using the SIB reagent or peroxidase 
labeled rabbit anti-equine IgG gave identical results. The reference EIA 
negative serum had no reactivity and at the 1:100 serum dilution used 
there was no background staining with the SIB reagent. The colloidal 
gold gave stable reactions while membranes processed with the peroxidase 
system faded with storage.
SIB for the diagnosis of EIA.
Analysis of 115 sera in the SIB test showed high correlation between 
results in the SIB test using HPLC purified p26 (40ng) and the USD A 
approved diagnostic tests for EIA including the AGID and C-ELISA tests 
(Table 4). As all the sera with equivocal AGID results would be 
considered as EIA test-negative by most trained personnel, the six serum 
samples with equivocal AGID reactions were recorded as negative for 
comparison (Table 4). There was 100% correlation for all sera with AGID 
reactions equal to or stronger than that of the International Reference 
Serum (Table 4). There was also 100% correlation between C-ELISA and 
the SIB test for six sera with equivocal AGID reactions including AGID 
test-negative samples from horses with a history of AGID test positive 
results. Two serum samples negative in AGID and C-ELISA, respectively, 
tested positive in the SIB test when HPLC purified p26 was used (Table 
4). These two samples were also negative in Western blots. The two 
samples gave no reactions when gp90 and recombinant p26 were used in
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the SIB test. EIA positive results were indicated by reactivity with gp90 
alone or in combination with p26 (Fig. 3). On the other hand, some sera 
with equivocal AGID reactions tested positive only with gp90 and 
recombinant p26 (Fig. 4) and required longer incubation times. The same 
sera (Flicker and FLA 253) were shown to have antibodies to gp90 and 
p26 in Western blots (Fig. 1, lanes 4 and 5).
Detection of EIAV antigens.
The presence of EIAV in infected cell cultures was assayed in the 
SIB test using rabbit serum to purified EIAV p26. Detection of virus 
antigens in supernatant medium of FEK cell cultures was determined in 
AGID and the SIB test. The SIB test could yield results within 4 h in 
contrast to the 48 h usually required for antigen detection by AGID. In 
persistently infected FEK cell cultures, EIAV p26 was detectable in 
supernatant fluids without any treatments. However, the detection of p26 
early during the infection required pretreatment of clarified supernatant 
media with PEG and disruption of precipitated virus with chaotropic 
reagents. Treatment of the precipitate with borate buffer, urea and SDS 
gave negative or more variable results possibly due to poor antigen 
binding on the support matrix or inadequate release of the major core 
protein. Disruption of precipitated virus with 4M KSCN consistently gave
positive results when supernatant fluids from infected cultures were 
tested. Supernatants fluids from uninfected cell cultures did not test 
positive with normal rabbit serum or rabbit anti-p26 serum. A positive 
antigen control (40ng of p26) was included in the test to check activity 
of the SIB reagent and the rate of the reaction, respectively (Table 5).
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DISCUSSION
EIA is currently diagnosed by detection of anti-EIAV antibodies in 
serum of infected horses in AGID and C-ELISA tests (5, 6). These
serological tests have been useful in controlling the spread of EIA. In 
certain cases, however, these tests fail to detect infected horses which 
appear to have low levels of anti-EIAV antibodies (6). This low 
sensitivity may result in the erroneous interpretation of the serological 
results. In these instances, Western blot procedures have proved more 
sensitive (6).
In this study, several serologic tests were evaluated for detection of
anti-EIAV antibodies. There was excellent agreement between AGID, C- 
ELISA, Western blot and the single-step immunoblot in samples with AGID 
test reactions equal in intensity to or stronger than the, international
reference serum. However, some serum samples may have extremely weak 
AGID reactions and be reported as AGID test-negative during routine 
testing for EIA. Such samples, designated as having equivocal AGID
reactions, had antibodies specific for EIAV gp90, gp45 and p26 as
revealed in Western blots. Moreover, all the equivocal AGID reactors 
were detected in C-ELISA. These results indicated that the AGID is not 
very sensitive for the detection of low levels of virus-specific antibodies. 
The Western blot procedure had the highest sensitivity for detection of
anti-EIAV antibodies in sera from experimentally or naturally infected 
horses. Most of the activity was to common antigenic determinants in 
EIAV gp 90 and gp45; activity to p26 was generally weak and variable.
The use of a rapid single-step immunoblot assay for detection of
anti-EIAV antibodies and EIAV antigens was evaluated. In this assay,
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specific antibody binds with its Fab-site to antigen attached to
nitrocellulose membrane and with its Fc-site to protein A conjugated with 
colloidal gold. This reaction and the blocking of unsaturated sites on the 
support matrix occur concurrently. Analysis of 115 sera in this assay 
using EIAV p26 showed that the test had a comparable level of
performance to that of USDA approved tests for EIA. Disrupted purified 
virus had low specificity probably as a result of cross-reactivity of
natural equine antibodies with cellular or serum proteins in the virus 
preparation. Because of the high sensitivity of the detecting reagent only 
highly purified antigens should be used to avoid non-specific reactions. 
Two serum samples negative in AGID, C-ELISA and Western blots gave 
positive reactions in the SIB test using HPLC purified p26. These "false 
positive" SIB reactions may be due to either non-specific reactions 
possibly due to high amounts of pure p26 used or to the recognition of 
determinants in the purified p26 by antibodies to other equine
retroviruses. This is deserving of further study. However, analysis of
serum samples with gp90 and recombinant EIAV p26 expressed in E. coli 
gave the expected results including negative results for the two sera with 
"false positive" SIB results, indicating that these combination of viral 
antigens should be used for high sensitivity and specificity of the SIB 
test. The results also showed that recombinant p26 expressed in E. coli 
maintained its antigenicity for anti-EIAV antibodies. Moreover, the 
higher quantities of recombinant p26 required to give intense color
change with sera that had weak reactions in AGID test did not lower the
specificity of this test. The reactions of two sera with equivocal AGID 
reactions showed reactivity with gp90 and recombinant p26 indicating that
I l l
sensitivity approaching that of the Western blot could be achieved in the 
SIB test. These results were in agreement with our previous reports 
indicating that all horses with a history of AGID test-positivity contained 
antibodies to the virus major envelope glycoprotein which reacted with 
apparent group-specific determinants (6, 13). Thus, the use of EIAV 
recombinant p26 and gp90 antigens in the SIB test would provide a 
sensitive and specific test that is inexpensive, rapid and suitable for any 
laboratory or field setting.
The Western blot procedure was shown to be highly sensitive for 
diagnosis of EIA in horses with levels of anti-EIAV antibodies that are 
below the sensitivity of the AGID and C-ELISA. This procedure, 
however, is expensive and not practical for the routine diagnosis of EIA 
and other viral infections. The SIB procedure is not dependent on 
expensive equipment and can detect presence of specific antibodies to a 
variety of antigens spotted on the same support matrix. The combination 
of different viral proteins on the same support matrix, e.g., gp90 and p26, 
was useful in detecting anti-EIAV antibodies in sera with low levels of 
antibodies to either protein. Use of combinations of purified preparations 
that represent the most immunogenic and antigenic proteins of a virus 
should give SIB test high sensitivity and specificity without the high 
costs of a conventional Western blot.
Production of EIAV in persistently infected cell cultures was easily 
monitored in the SIB test using rabbit anti-EIAV p26. The test had high 
specificity for EIAV antigens and detectable antigens were present in lil 
of supernatant fluids from persistently infected cell cultures with or 
without pretreatment with PEG and chaotropic reagents. The detection of
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EIAV antigens in the AGID test takes at least 48 h. (1). In this study, 
viral antigens could be detected in the SIB test with anti-p26 serum 
within 2-5 h. The SIB test therefore presents a rapid method for the 
detection of anti-EIAV antibodies in serum of horses and EIAV antigens 
in the supernatant fluids of infected cell cultures, respectively.
In contrast with other immunoassays, the SIB test did not require 
pre-blocking of unsaturated sites in the antigen support matrix, washes, 
or second antibody which in most cases needs further processing for 
either chromogenic reactions or autoradiography. Moreover, the test was 
easy to interpret as a contrasting color developed at the antigen sites in 
the presence of specific antibody. The test holds great potential for wide 
application in the detection of antibodies with specific antigen or 
detection of antigen with specific antisera, respectively. In viruses where 
distinct serotypes exist, this test can be of great epidemiological value 
especially when serotype specific antigens or synthetic peptides are used. 
Use of colloidal gold conjugated with proteins that have high affinity for 
the Fc-portion of immunoglobulins from many species would greatly 
increase the sensitivity, reduce the turnaround time and broaden the 
spectrum for the use of this assay with sera from different species.
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Table 1. Sensitivity of SIB test for HPLC purified p26 and recombinant 
p26 using EIA positive equine sera and EIA negative reference 
serum.
AMOUNT OF ANTIGEN (ng/microliterl 
ANTIGEN AGIDa 200 100 50 25 12 6 3
v .
Sb + + + + + + +
W + + + + - - -
N .............................................................
S + + + + + - -
w  + + . . . . .
N .............................................................
a AGID activity for anti-EIAV antibody indicated as strong (S), 
weak (W) or negative (N) (see text for detail),
b sera tested at 1:100 dilution in the SIB reagent.
+ positive for specific antibody after 3 h. 
negative for specific antibody after 3 h.
p26
rec-p26
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Table 2. The kinetics of SIB test for equine and rabbit sera using 40ng of 
HPLC purified p26.
SERUM
SOURCE DILUTION 5
TIME IN MINUTES 
15 60 120 240
HORSE 1:10 - - - 1 + 2 +
(S) 1:100 - - 1 + 1 + 3 +
1:1000 - - - 1 + 1 +
HORSE 1:10 - - - - 1 +
(W) 1:100 - - - 1 + 2+
1:1000 - - - - -
RABBIT 1:10 1 + 2 + 3 + 4 + 4 +
(S) 1:100 1 + 2+ 3 + 4 + 4 +
1:1000 1 + 1 + 2+ 4 + 4 +
(S) Reference horse serum or rabbit anti-p26 serum with strong
AGID reaction.
(W) Positive horse serum with weak AGID reaction.
(-/ +) negative or positive for specific antibody (number of pluses
indicate intensity).
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Table 3. Correlation of AGID, C-ELISA and Western blot in the detection 
of anti-EIAV antibodies in equine sera.
C-ELISA WESTERN-BLOT*
AGID Number #  Positive #  Positive to:
reactions tested gp90 gp45 p2<
Negative 9 1 2 2 2
Equivocal 6 6 6 5 5
Weak positive 38 38 38 38 38
Positive 25 25 25 25 25
serum samples tested at 1:50 dilution against prototype cell culture 
adapted EIAV.
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Table 4. Comparison of AGID, C-ELISA and SIB serologic assays for 
detection of anti-ELAV antibodies in equine sera.
AGIDa Number C-ELISA!* SIB£
reactions Tested #  POS. #  NEG. #PO S. #  NEG,
Negative 15 7 8 9 6
Positive 100 100 0 100 0
a Interpretation of AGID explained in text.
b Sample positive if intensity of color was equal to or lower than that
of the positive reference sample. 
c SIB test using 40ng of HPLC purified p26. Sera were diluted 1:100 in
the SIB reagent and the test was scored after 4 h.
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Table 5. Detection of EIAV antigens in the supernatant fluids of 
persistently infected cell cultures.
ANTIGEN TREATMENTS
Cell Borate Urea SDS KSCN p26b
Cultures .05M 8M 5% 4M
Infected - + + + + + NA
Uninfected - - - NA
NA + + +
a Clarified supernatant medium was treated with 40% PEG and processed 
as described in the text. 
b HPLC purified p26 (40ng) was included as positive control antigen.
- o r  + indicate negative or positive results after incubating each 
preparation with 1:100 dilution of rabbit anti-p26 serum in the SIB 
reagent. The number of pluses indicate color intensity.
NA- not applicable.
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Fig. 1: Western blot profiles of selected serum samples against the
prototype cell adapted strain of EIAV are shown in lanes 1-10. 
The reactivity of one serum sample against prototype EIAV (lane 
10), isolate A/1 (lane 11) and isolate A /4 (lane 12) is included 
for comparison. Serum samples in lanes 1-12 are as follows: (1) 
reference ELA-negative horse serum; (2) international reference 
serum; (3) 10165; (4) Flicker; (5) FLA 253; (6) mare 51; (7) mare 
40; (8) Stallion 6; (9) 10126; and (10-12) FLA 191.
123  4 5 6  7 8910111?f iU jf n ; | ] | ! m w  ■
Western blot analysis of equine sera with the SIB reagent or 
peroxidase labeled rabbit anti-equine IgG. Virus specific 
antibodies are tested in panel A with the SIB reagent and panel 
B with peroxidase labeled rabbit anti-equine IgG, respectively. 
Reference EIA negative equine serum is tested in lane 0 and EIA 
positive sera are tested in lanes 1-2 of panels A and B, 
respectively.
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Fig. 3: Detection of antibodies to EIAV gp90 and p26 in SIB test. Sera 
with weak AGID reactions are tested in lanes 1-4 and sera with 
strong AGID reactions are tested in lanes 5-8. Reference EIA 
negative equine serum is tested in lane 0. Each serum is tested 
against gp90 (top spot), viral p26 (middle spot) and recombinant 
p26 (rec-p26) (bottom spot). Intense spots at gp90 or p26 sites 
indicate presence of EIAV specific antibodies.
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Fig. 4: SIB test analysis of equine sera with equivocal AGID reactions.
Reference EIA negative horse serum is tested in lane A and 
reference positive EIA horse (Lady) serum is tested in lane D, 
respectively. Sera with equivocal AGID reactions (Flicker and 
FLA 253) are tested in lanes B and C, respectively. All sera 
were tested against gp90, HPLC purified p26 (v-p26) and 
recombinant p26 (r-26).
CHAPTER FIVE
GENERAL DISCUSSION
This study was conducted to characterize variants of EIAV recovered 
from infected Shetland ponies and variants generated in cell culture, and 
to determine the nature of specific antibody responses during infection. 
The course of EIA observed in this study was consistent with previous
descriptions (14, 18, 27). Seven virus isolates were recovered from 
plasma collected during febrile episodes. In published reports isolates 
A/1-4 were designated as P3.3-1, P3.3-2, P3.3-3 and P3.3-4 for passage
level in ponies (P3), animal number (3, 4, 5), and febrile episode (1, 2, 
etc.) (13,30).
Recurrent febrile episodes were observed during chronic EIA and 
viruses recovered from these episodes were shown to be serologically 
different. The rate of emergence and the number of serologically distinct 
variants in each animal was different. The demonstration that isolates 
recovered during febrile episodes 4-5 weeks apart were only neutralized 
by homologous sera and that definite antigenic changes could be 
identified with MAbs confirmed that EIAV undergoes rapid antigenic 
variation. This study extends previous reports which have shown that
during persistent infection, EIAV undergoes rapid structural and antigenic 
alterations in gp90 and gp45 which appear to result from point mutations 
in the env gene (13, 22, 28, 29, 30, 31). In addition, this study
demonstrated that the rapid variation of EIAV observed in persistently 
infected animals has an immunological basis as the neutralizing specificity 
of selecting serum appeared to determine the serological divergence of
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the in vitro variant.
The generation of an in vitro variant of EIAV suggested that mutant 
viruses that appear during virus replication require a selecting medium in 
order to replace parental virus. In the presence of neutralizing antibody, 
the parental virus and the closely related mutant viruses are neutralized 
while more divergent mutants continue to replicate. The presence of 
neutralizing antibodies in infected cell cultures provide a selection 
pressure that operates on virus variants generated by an independent 
mechanism of genetic variation of the viral genome. Non-neutralizing 
antibodies may interfere with virus maturation by causing "patching and 
capping" of cell membrane-bound viral glycoproteins. However, as the 
virus can also bud into cytoplasmic vacuoles, the effect of non­
neutralizing antibodies may be minimal. As most of the genetic variation 
is likely to occur during reverse transcription of the viral genome, the 
replication of virus in cells that are susceptible to lytic-infection will 
increase the rate at which genome variation occurs. In contrast, the 
replication of virus in persistently infected cells is likely to limit the rate 
of genome variation as the majority of the virus probably replicates from 
proviruses established during the first few rounds of infection when 
susceptible uninfected cells are still available. Once maximum cell density 
in culture is achieved and the pool of susceptible cells has been infected, 
homologous superinfection which is required to maintain cycles of reverse 
transcription may be prevented by mechanisms which would result in a 
decrease in expression of viral receptor. Such a process may proceed via 
receptor interaction with shed viral envelope glycoproteins followed by 
receptor-ligand internalization, formation of receptor-ligand complexes
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between nascent cellular and viral envelope proteins or reduction in the 
steady state synthesis of the receptor molecules. A similar mechanism of 
receptor down-regulation occurs in T cells persistently infected with HIV 
where expression of the HIV receptor (CD4) on cell surface is decreased 
through reduction of mRNA synthesis and the formation of complexes of 
available CD4 with viral envelope products (9). The faster rate of 
emergence of antigenic variants in vivo may thus be explained by the 
lytic infection of susceptible cells including monocytes and macrophages 
accompanied by selection pressure operating at both the B- and T-cell 
epitopes.
The ability of heterologous serum to partially neutralize the in vitro 
virus variant suggested that either the specificity of the selecting serum 
determines the serological divergence of the new virus or more than one 
site is involved in virus neutralization. These possibilities are not 
mutually exclusive. More than one site is involved in the neutralization 
of many viruses including influenza virus and HIV and mutants that resist 
neutralization by one MAb may retain their sensitivity to neutralization 
by MAbs 'mapping at different epitopes (10, 35). Results presented in this 
study demonstrated that antigenic variation allows EIAV to infect host 
cells in the presence of immune sera. The evolution of new virus 
variants in vivo may eventually be controlled by the presence of 
immunological specificities that can accommodate a variety of antigenic 
alterations. Knowledge of these immunological specificities and the viral 
antigens that elicit them will be necessary for the design of effective 
vaccines.
The humoral responses to EIAV during persistent infection were
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monitored by AGID, Western blotting and virus neutralization. Specific 
IgG to gp90 was demonstrable within 2 weeks after infection. The rate 
of appearance of IgG to gp45 was slower than that observed for gp90 and 
p26. Although this early IgG had no virus neutralizing activity in vitro. 
it is likely that in vivo, antibodies binding to these proteins can be 
protective by complement or cellular dependent mechanisms. Furthermore, 
specific IgM responses which were not monitored in this study may have 
important protective roles before the appearance of specific IgG. Type- 
specific neutralizing antibodies appeared within 2 months after infection. 
These results are in agreement with previous reports indicating that 
neutralizing antibodies appeared 45-87 days after infection and peaked 3-5 
months after infection (17). The broad neutralizing activity of serum 
collected late in the infection could have on the one hand resulted from 
sequential stimulation of the immune system with multiple virus variants 
as may have been the case with ponies A and B. On the other hand, the 
specificity of neutralizing antibody may have broadened through repeated 
stimulation of the immune system with one virus strain as might have 
been the case with pony C.
Stimulation of the immune system with either sequential virus strains 
or one virus strain has been shown to elicit broadly neutralizing antibod­
ies in sheep infected with visna virus or in chimpanzees infected with a 
strain of HIV, respectively (24, 25). However, the facility with which the 
lentiviruses alter their surface glycoproteins (3, 7, 8, 29, 30) suggests 
that during persistent infections the immune system is stimulated by 
"quasispecies" (5) rather than a monotypic strain of virus. The 
broadening of the humoral response may result from stimulation of the
immune system with a spectrum or "cock tail" of virus variants, which 
may differ in their replication but not immunogenic potential. The virus 
populations that predominate in cell culture represent variants capable of 
replicating extensively under the culture conditions. This may not be the 
variant that replicates predominantly in vivo where a variety of target 
cells are likely to be involved. The rate of appearance of specific IgG 
and recurrences of acute EIA imply that conserved epitopes are not likely 
targets for protective immune responses. The failure of antibodies 
binding to these conserved epitopes to control virus replication suggest 
that: the virus replicates in sites with low concentrations of antibodies; 
or the virus is predominantly maturing into cytoplasmic vacuoles; or the 
relevant antigens are not expressed on infected cells. On the other hand, 
shedding of envelope proteins which has been recognized for other 
lentiviruses may direct immune mechanism, e.g., cytotoxic T cells, 
antibody-dependent cell-mediated cytotoxicity (ADCC) and complement 
away from infected cells. The course of EIA and the early appearance
of specific IgG which bind to homologous and heterologous virus isolates 
but display type-specific neutralizing activity suggests that protective 
immune responses broaden as a result of stimulation with a spectrum of 
viruses with modifications at specific B- and probably T- cell epitopes.
The delayed appearance of antibodies capable of neutralizing virus in 
vitro suggests that other mechanisms may be important in the control of 
viremia. Leukocytes with direct cytolytic activity appear 14 to 18 days 
after infection with EIAV (6) suggesting minor role in controlling viremia 
which in this study peaked 2 to 3 weeks after infection. Equine IgG but 
not IgG(T) has been shown to mediate antibody dependent cellular
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cytotoxicity (ADCC); however, leukocytes from infected horses failed to 
lyse cells infected with EIAV but lysed heterologous target cells 
indicating a specific inability for these cells to eliminate EIAV infected 
cells (6). The absence of effective ADCC during infection with EIAV may 
explain the inability of horses to control virus replication despite high 
levels of binding antibodies. On the other hand, it would be of interest 
to find out whether horses who produce high levels of IgG(T) succumb to 
recurrent episodes of acute EIA since this subclass of IgG inhibits both 
ADCC and complement fixation (6, 21). Control of viremia in the absence 
of neutralizing antibody can be mediated by interferon, fever, and 
complement with or without specific antibody. In other retrovirus 
systems, the transmembrane protein has been shown to activate the 
classical pathway of complement and to bind C l (1, 4). The acute signs 
of EIA i.e., fever and depression, are suggestive of increased macrophage 
function probably in response to opsonized virions. Components of 
complement and interleukin-1 from activated macrophages may be 
responsible for fever, depression and the low levels of platelets seen in 
acute EIA.
The variable course of EIA may be due to many factors including 
host susceptibility and major histocompatibility genes, i.e. equine 
leukocyte antigens (ELA), virus strain and intercurrent disease processes. 
In this study, each pony had a different course of infection after 
receiving the same plasma. It was difficult to explain the variability in 
the course of EIA based on the kinetics of humoral response as no 
difference was detected. Other host factors are likely to be important. 
It is likely that ponies with appropriate ELA haplotypes become optimally
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stimulated by the mosaic of "critical" B- and T-lymphocyte epitopes in 
the parent virus population. Such horses would remain afebrile after the 
first episode i.e., pony C. Conversely, ponies with inappropriate ELA 
haplotypes would be incapable of recognizing all the "critical" epitopes in 
the parent virus population. Such ponies i.e., ponies A and B, would 
allow virus mutants to leak through the narrow immune spectrum until a 
sufficient spectrum of immunological memory is elicited. At present it is 
difficult to predict the immunological factors that are important in the 
control of virus replication and cessation of recurrent febrile episodes. It 
is apparent that humoral responses either appear too late to arrest 
disease progression or virus is spreading from cell-to-cell causing 
pathology regardless of the neutralizing specificity of antibodies. The 
influence of ELA haplotypes on the pathogenesis of EIA can be studied 
with recipients sharing a single haplotype. This can be achieved by 
infecting genetically identical horses obtained through embiyo splitting.
The ability of lentiviruses to undergo antigenic variation presents a 
formidable challenge to the development of effective immunogens. The 
genomes of sequential EIAV isolates demonstrate differences in their 
nucleotide sequence (29, 30). Within the gp90 region, conserved, variable 
and hypervariable regions have been identified; most of the amino acid 
substitutions in the hypervariable region involved potential N-linked 
glycosylation sites (30). Alterations of potential glycosylation sites may 
explain the variation in glycopeptide maps previously observed in a set of 
parallel third passage isolates (31). The variation involving peptide and 
glycosylation patterns in each virus isolate may alter antigenicity, thus 
allowing each virus strain to circumvent specific immune factors elicited
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by progenitor viruses. In influenza virus, removal of a potential
glycosylation site in H5N2 was associated with high virulence as a result 
of unmasking of a cleavage site (16). It is likely that alteration of
glycosylation patterns of EIAV may alter host range, immunogenicity and 
antigenicity. Of interest in this regard is the apparent resistance of
wild-type EIAV to infect cultured equine fibroblasts. The level at which 
this restriction operates is currently not known. In other lentivirus 
systems, restriction has been shown to operate at the level of host cell 
recognition (19, 20). The failure of wild-type virus to replicate in 
cultured equine fibroblasts suggests that the wild-type virus predominantly 
replicates in a different cell type in vivo. Different glycosylation 
patterns in wild-type virus may alter recognition by putative prototype 
virus receptor on FEK cells. This can be explained in the following
hypothetical scenario: during infection of ponies with prototype virus only 
spontaneous mutants with altered host cell specificity are capable of 
infecting target cells associated with replication of EIAV. Conversely, 
only those spontaneous host range mutants are capable of replicating in 
FEK cells during virus reisolation from plasma. In both directions, only 
a very minor virus population of spontaneous mutants is initially present. 
Accordingly, virulence of prototype virus increased with serial passage in 
ponies (26) probably as a result of predominant virus population gradually 
shifting from an "FEK-population" to an "in vivo population". A reverse 
shift in population may occur during virus reisolation in FEK cells which 
takes at least 6 weeks of culture. The ability of the prototype virus to 
replicate in this manner suggests a hot-spot genetic defect that is absent 
in wild-type virus. Clearly a need to explore the in vivo target cells for
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EIAV exists and previous data implicating monocyte/macrophages on 
immunofluorescence data need to be extended with technology capable of 
distinguishing between passive antigen expression (phagocytosis of viral- 
antibody complexes) and authentic virus infection i.e. proviral DNA. The 
isolation of monocytes and lymphocytes from horses with chronic EIA and 
their fusion with FEK cells can determine whether the restriction of 
wild-type EIAV to replicate in this cells is at receptor recognition.
In EIA, after a number of clinical episodes, infected horses may die 
or remain asymptomatic. The eventual cessation of recurrent clinical EIA 
is thought to have an immunological basis (2). The neutralizing activity 
of convalescent serum antibody increased with time and was highly cross­
reactive late in the infection. This observation leads to the suggestion 
that given enough immunological stimulation, e.g., immunization with 
several virus strains, horses would develop broadly reactive immune 
responses. However, the role of neutralizing antibody in the pathogenesis 
of lentivirus infections is challenged by the frequent observation that the 
level of neutralizing antibody does not appear to influence the course of 
disease. For example, in this study all the ponies died despite the 
presence of neutralizing antibodies that were detectable as early as 2 
months after infection. Similarly, neutralizing antibodies are present in 
the sera of both asymptomatic HIV seropositive persons and in AIDS 
patients suggesting that naturally developing neutralizing antibody offer 
little protection (33, 34). Moreover, immunization of chimpanzees with 
vaccinia-HIV env recombinants did not avert challenge infection despite 
the presence of specific antibody and T-cell responses (11). Analysis of 
the humoral and cellular immune responses in healthy seropositive
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individuals (i.e., ponies who have survived for long periods following 
infection) might shed some light into the nature of long-term protective 
immune mechanisms. In addition, full knowledge of the interaction of 
these lentiviruses with other intercurrent pathogens in the disease process 
may aid in the design of disease management protocols. The recognition 
that herpes viruses and lentiviruses may possess transactivating genes 
raises the speculation of potentiation of viral gene expression during dual 
infection with these viruses and a possible fatal outcome.
The diagnosis of viral infections by detection of specific antibody is 
limited to the phase of infection when immunological responses are 
measurable. The time between infection and detection of infection by 
serology is variable in most viral infections and represents a critical 
window in disease control measures. Of greatest concern in this regard 
are the viruses which cause persistent viremia in their hosts since 
infected individuals can directly or indirectly disseminate virus for long 
periods prior to diagnosis. For this reason, technology that can directly 
determine the presence of virus in an individual is most desirable. In the 
absence of such technology, continued search for simpler, inexpensive and 
sensitive serological tests is implied. In this study, a single-step 
immunoblot method was evaluated for its application in the rapid 
diagnosis of EIA. The SIB test relies on the binding of colloidal gold
conjugated with protein A to the Fc- portion of specific antibodies that
react with antigens attached to a support matrix. By reacting test sera
with both gp90 and p26, a level of sensitivity and specificity similar to 
that of the approved diagnostic tests for EIA was achieved. This test 
also proved more efficient in detection of EIAV antigens in the
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supernatant fluids of persistently infected cell cultures.
In a limited study, a rabbit was immunized with lentil-lectin purified 
glycoproteins of prototype EIAV. Immune serum contained titers 103-6 
in ELISA using purified virus. The antibodies reacted with several virus 
isolates including prototype EIAV. Immunoblot analysis of this serum and 
sera from rabbits immunized with whole or detergent disrupted prototype 
EIAV indicated strong activity to gp90 and low activity to gp45. 
However, the anti-glycoprotein serum failed to neutralize homologous or 
heterologous virus isolates. In contrast, sera from rabbits immunized 
with whole or detergent disrupted virus had high neutralizing activity 
(Issel, unpublished results). The failure of the rabbit serum to neutralize 
virus suggested that soluble purified glycoproteins may not possess the 
epitopes that are important for eliciting neutralizing antibodies. These 
results indicated that for the desired immune response to be achieved the 
antigens will have to be presented in a form that ensures native 
conformations. In a pilot study, treatment of prototype EIAV with 
disulfide-activating reagents such as 2,2’-dithiobis-m-nitropyridine did not 
lead to the formation of heterodimers of gp90 and gp45 (data not shown). 
In other retroviruses, heterodimers of the outer envelope glycoprotein and 
the transmembrane protein have been shown to elicit more potent 
protective immune responses than the individual proteins (12, 32). For 
viruses that cannot form such heterodimers, immunostimulating complexes 
(ISCOMS) of glycosides with the glycoprotein inserted in a multimeric 
form (23) would be a better form of antigen presentation.
The demonstration that the hydrophobic amino terminus of gp41 
contains a fusogenic domain responsible for the fusion event following
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gpl20-CD4 binding and that mutations in this region interfered with 
membrane fusion (15) suggests a more significant role for this protein in 
the infection process. In other viruses, membrane fusion is a function of 
the hydrophobic amino terminus of an integral membrane protein that 
undergoes maturation by proteolytic cleavage, e.g the orthomyxoviruses
and paramyxoviruses. It is likely that binding of antibodies to the outer 
envelope and the transmembrane protein mediate cooperative 
neutralization which is more potent than that achieved by antibodies to 
either protein alone. The time of appearance of neutralizing antibodies in
horses with EIA suggest that antibodies to gp90 and gp45 may cooperate 
in virus neutralization. Furthermore, the transmembrane location of gp45 
may facilitate antibody dependent complement mediated cytolysis and 
virolysis. Information on the immunochemistry of the glycoproteins of 
EIAV and their specific roles in the early events in virus replication
cycle will be necessary in designing strategies for production and
purification of non-replicative immunogens for control of EIA. As 
antigenic variation in this virus appears to be unlimited at the population 
level, a need to determine clusters of immunodominant and more 
genetically stable variants from the panel of those generated in vivo and 
in vitro is evident. Trials with inactivated immunodominant virus variants 
may open the way for the development and use of cock tails of subunit 
vaccines that will be protective.
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